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4. ABSTRACT 
Transdifferentiation entails the direct conversion between terminally differentiated cells, 
without passing through the pluripotent state. Strikingly, through the exogenous expression 
of few transcription factors (TFs), the starting cell epigenome is restructured, allowing the 
generation of a cell that can be embryologically distant. This is the case of BAM (i.e., 
Brn2, Ascl1, Myt1l) factors, whose transduction in mouse embryonic fibroblasts (MEFs), 
deriving from the mesoderm, allows their transdifferentiation into induced neuronal cells 
(iNs), which derive instead from the ectoderm.  
The gene networks that characterize each MEFs-to-iNs transdifferentiation phase have 
been recently described, but to date it is still unclear how BAM factors guide such a 
conspicuous epigenetic remodelling. 
MLL1 and MLL2 are two H3K4 trimethylases, belonging to the Trithorax protein family, 
discovered for their role in the regulation of Hox genes, which are fundamental for cell 
identity specification. Although during neuronal development and differentiation the 
function of the Trithorax axis has not been clearly identified, some hints suggest the 
involvement of MLL1 and MLL2 in both in vivo and in vitro neuronal differentiation.    
Therefore, I studied the role of MLL1 and MLL2 during MEF-to-iNs transdifferentiation. 
Whether transdifferentiation could envisage the same temporal epigenetic changes of 
physiological differentiation is still an open debate. What is evident is that in these two 
types of lineage specification (normal differentiation and transdifferentiation) starting cells 
have very different epigenomes, so a complete overlap of the epigenetic remodelling steps 
seems implausible. However, transdifferentiation remains a good tool to gain more insights 
both on neuronal differentiation and on the driving factors of transdifferentiation itself, 
which are often “terminal selector genes” or TFs fundamental during cell specification in 
development. 
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First, I extensively characterized the impact of the deletion of either Mll1, Mll2 or both, 
measuring transdifferentiation efficiency and iNs maturation. In particular, I showed that 
the absence of MLL1 does not affect neither transdifferentiation efficiency nor iNs 
neuronal morphology. Mll1 deletion is only detrimental for the survival rate of 
transdifferentiating MEFs. On the contrary, transdifferentiation efficiency is compromised 
in the absence of Mll2, and Mll2-/- iNs show an impairment in neurite elongation. The co-
deletion of Mll1 and Mll2 impinges on cell viability as the knock-out of Mll1 and it further 
exacerbates the Mll2-/- transdifferentiation defect. Moreover the few Mll1-/-Mll2-/- iNs 
generated have very short neurites. These results suggest a role for MLL2-mediated H3K4 
methylation in the control of transdifferentiation. Therefore, I defined the direct and 
indirect MLL2 targets through the integrative analysis of: i) the RNA-seq on iNs, ii) the 
ChIP-seq for MENIN, the specific common subunit of MLL1 and MLL2, for the 
delineation of the direct MLL2 targets which were not compensated by MLL1 and iii) the 
H3K4me3 ChIP-seq, to identify which are the genes that need to be trimethylated to allow 
transdifferentiation. I showed that in the absence of Mll2 a conspicuous fraction of the 
transcriptome is down-regulated and/or loses the H3K4me3 mark. Therefore, MLL1, 
despite being the MLL2 homolog, is not capable of compensating for the absence of MLL2 
during transdifferentiation. Moreover, many deregulated genes (either differentially 
expressed or differentially marked by H3K4me3) are linked to neuronal differentiation and 
maturation, as expected by the phenotype analysis. Finally, among the others, also the 
Polycomb axis is dysregulated, suggesting its possible involvement in the Mll2-/- defective 
transdifferentiation. 
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5. INTRODUCTION 
5.1 Cell fate plasticity 
5.1.1 Cell fate plasticity: a historical perspective 
 
From an evolutionary perspective we could expect that the genome size increases along 
with the organism complexity. Paradoxically, higher order organisms do not necessarily 
have both a higher DNA content and a greater number of genes. This is the so-called C-
value enigma or, indeed, paradox (C.A. Thomas Jr, 1971). However, the layers of 
epigenetic control of gene expression and gene accessibility co-evolved with genome size1-
3. This, on one side, could partially reconcile the C-value enigma. Moreover, the epigenetic 
configuration, since the cells of an organism have the same DNA content, defines the 
identity/the lineage commitment of the considered cell. 
Conrad Hal Waddington was the father of the term epigenetics, defined as “the branch of 
biology which studies the causal interactions between genes and their products, which 
bring the phenotype into being”4. He also stated, regarding “the “whole complex of 
developmental processes” that connects genotype and phenotype that “It is convenient to 
have a name for this complex; ‘epigenotype’ seems suitable”5,6. 
With the growth of the knowledge in this topic, epigenetics, nowadays, comprehends all 
the inheritable modifications at the DNA level, but not to its sequence, and at the histone 
proteins associated to DNA.  
Conrad Hal Waddington also fathered the seminal metaphor of the epigenetic landscape. 
He depicted the pluripotent cell as a marble rolling down the epigenetic landscape (Figure 
1). Every valley and hill that the marble encounters represents a different lineage choice, 
respectively more or less energetically favourable. Progressively the marble becomes more 
and more committed until it reaches its final valley: the terminally differentiated state. We 
could envisage the cell/marble modifying its epigenome along the descent and therefore 
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we could consider that each step of differentiation is defined by a different epigenome 
configuration (Figure 1).  
Due to the unfavourable energetic condition, the marble was considered unable to get back 
on top of the epigenetic landscape (i.e., back to pluripotency) and to cross the epigenetic 
hills that separate the diverse lineage fates (i.e., change commitment).  Although the 
metaphor of differentiation remains valid, the notion of irreversibility of the fate choice has 
by now been surpassed. 	
                           
Figure 1: The Waddington landscape model 
In the Waddington model the pluripotent cell is depicted as a marble rolling down the epigenetic 
landscape until its final differentiated state is reached (From Waddington, 1942). 
 
5.1.2 Epigenetics: crossing the barriers 
 
In 1950s, Briggs, King and Gurdon, taking advantage of the Somatic Cell Nuclear Transfer 
(SCNT) technique, demonstrated that some components of the cytoplasm of an enucleated 
frog oocyte, at that time unidentified, were able to “reprogram” the transferred nucleus of 
somatic, terminally differentiated Xenopus laevis cells, back to pluripotency, allowing the 
formation of new tadpoles7,8. SCNT was demonstrated effective also in different 
organisms, such as the Mus musculus (Figure 2d). This discovery set the foundations for 
the seminal study of Yamanaka and Takahashi of reprogramming of differentiated cells 
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into induced Pluripotent Stem Cells (iPSCs) in 2006 (Figure 2b)9. Yamanaka and 
Takahashi showed that through the ectopic expression of Oct3/4, Sox2, Klf4 and c-Myc, 
four transcription factors (TFs) important for the maintenance of pluripotency and for the 
proliferation of Embryonic Stem Cells (ESCs), they were able to reprogram mouse 
fibroblasts, both embryonic and adult, into pluripotent cells. iPSCs expressed pluripotency 
markers, formed teratomas if transplanted in nude mice and contributed to mouse 
development when they were introduced into the blastocyst, three fundamental features of 
ESCs and hallmarks of pluripotency9. The reprogramming protocol has been adapted also 
to human cells10,11 and to cells of different lineages12-15, revolutionizing the stem cell field. 
The discoveries of Gurdon and Yamanaka showed that lineage-specific TFs are able to 
reprogram and reset the epigenome of a differentiated cell16: the epigenome, therefore is 
not fixed in a static and incontrovertible configuration (Figure 2b). 
Another proof that lineage specification of a cell is not irreversible came from cell fusion 
studies. Heterokaryons are non-dividing multinucleated cells that originate by fusion of 
cells with different identities. In the heterokaryons formed by mouse myotubes and 
differentiated human cells, human muscle cell markers are up-regulated in the latter17 
(Figure 2e). This evidence shows that the identity of differentiated cells, and therefore their 
epigenetic configuration are actively maintained by instructive factors, able to orient the 
fusion partner to their lineage. These TFs are called also “terminal selectors genes”, which, 
by controlling a plethora of effector genes, directly specify the cell identity during 
development and preserve it in mature cells. 
In 1979 Taylor and Jones demonstrated that treating mouse fibroblasts with the 
demethylating agent 5-azacytidine (5-azaC) they formed myotubes18. In the following 
years the helix-loop-helix TF Myogenic Differentiation 1 (MYOD1) was identified as the 
main driver of myogenic conversion19. The direct passage, without passing through the 
pluripotent state, between differentiated cells of diverse lineages is called 
transdifferentiation or cell conversion (Figure 2c and 2f). Nowadays there are many other 
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examples of experimental transdifferentiation, also between cells that derive, unlike 
fibroblasts and muscle cells, from different germ layers and that therefore do no share the 
majority of the epigenetic marks.  
 
 
 
Figure 2: The exceptions to the Waddington’s model 
a. Cell development path according to Waddington’s model. b. Reprogramming to pluripotency. 
Unexpectedly the marble, from the differentiated state, can also roll back to the top (the pluripotent 
state). c. Transdifferentiation. Cells can convert into other differentiated cells, both deriving from 
the same progenitor (short arrow) and with different embryological origins (long arrow), without 
passing through the pluripotent state. d. Schematic of somatic cell nuclear transfer. Through the 
transfer of a somatic nucleus into an enucleated oocyte, the nucleus-receiving cell is reprogrammed 
to pluripotency, from which also an entire organism can be derived. e. Schematic of Cell Fusion 
a	
b
c	
d
e
f	
		 21	
between different cell types, which leads to the formation of heterokaryons. f. Schematic of 
transcription factors-mediated reprogramming towards different cell fates. 
(Adapted from Ladewig et al., Nature Reviews Molecular Cell Biology 2013 and Vierbuchen and 
Wernig, Molecular Cell 2012) 
 
These breakthrough studies amplified the vision of Waddington. Cell identity is 
dynamically preserved by lineage instructor factors that, on one side, keep lineage specific 
cascades active (i.e., SCNT and heterokaryons studies). On the other side they 
epigenetically maintain non-lineage specific signalling switched off (i.e., 5-azaC 
experiments). This equilibrium is, however, perturbable, precisely thanks to the ectopic 
expression of specific TFs for different lineages. Cells are therefore more plastic than 
previously thought. Although the hierarchical epigenetic landscape is still perfect to depict 
cell differentiation, it does not apply to the description of reprogramming and 
transdifferentiation. One alternative representation is the “epigenetic disc” proposed by 
Brüstle and colleagues (Figure 3)20. Since it is now almost equally simple to reprogram 
cells to pluripotency and to differentiate or to transdifferentiate them, the epigenetic disc is 
a model where all the cell identities are holes (the unstable pluripotent state is an open 
hutch) lining the border of a disc. In this representation, a slight tilt of the disc (the 
expression of specific TFs) is sufficient to make the marble (i.e., the cell) roll towards the 
desired cell lineage, abolishing the concept of hierarchies.  
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Figure 3: The epigenetic disc model 
The cell is depicted as a marble, as in Waddington’s model, but all the cell identities are 
represented as holes along the margins of a disc, thus eliminating the hierarchy embedded in 
Waddington’s model. By tilting the disc (i.e., the transduction of specific TFs), the marble can 
reach other differentiated states including the pluripotent one. Since pluripotency is a metastable 
condition, it is represented as an open hutch rather than a hole.  
(From Ladewig et al., Nature Reviews Molecular Cell Biology 2013) 
 
5.1.3 Stability of a differentiated cell  	
The identity of a cell is differently maintained depending on the cell type, through 
networks that are more or less stable. 
In cells that are highly plastic (e.g., B cells) this network could be as simple as a cross-
inhibitory regulation between two instructor TFs: the active one directs and maintains the 
current lineage, inhibiting the other that would be responsible for the alternative 
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specification (Figure 4a). In this case the ablation of the expressed TF would lead to the 
activation of the alternative pathway, and consequently to lineage switching. One example 
of this univocal type of cross-regulation is the misexpression of the CCAAT/enhancer 
binding protein α (C/EBPα) and C/EBPβ in B cells. These two TFs inhibit Pax5, the 
instructive factor for B cell commitment, leading to macrophages transdifferentiation21. 
Another case is the ablation of forkhead box L2 (Foxl2) gene, a TF fundamental for female 
gonad development, in granulosa and theca cells, which induces their transdifferentiation 
into Sertoli and Leydig cells22. Thus on one side, in the hierarchical tree of differentiation, 
the choice between two closely related cell lineages branches is exerted by the mutually 
exclusive expression of driver TFs. On the other side, since these cell types are 
developmentally proximal and in most of the cases deriving by the same progenitor, their 
epigenomes present only minor differences. Therefore the resetting of the lineage-specific 
epigenetic marks is not massive as in the case of transdifferentiation between cells deriving 
by different germ layers. 
In the case of stable/less plastic cells, instead (e.g., neurons) the sole ablation of the lineage 
specific TF or misexpression of the alternative TF are not sufficient to drive 
transdifferentiation in the mutually exclusive cell-fate, because of a higher internal 
regulation of the differentiation/maintenance pathway and a stronger blockade of the 
alternative pathway by epigenetic modifications (Figure 4b). One example is Nurr1, the 
fundamental TF for dopaminergic differentiation, which leads only to the down-regulation 
of some dopaminergic markers upon ablation in adult mice. On the contrary if it is 
embryonically deleted, this results in the totally absence of dopaminergic neurons23. The 
tighter regulation in the adult implicates a fine preservation of the integrity of the tissue.  
A third case comprises stable cells in which the two driver TFs activate pathways that have 
both a high internal regulation and that do not intersect (Figure 4c). This is also the case of 
cells deriving from different germ layers. 
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Figure 4: The Networks preserving cell identity 
a. Cell identity is controlled only by one TF (A), which inhibits the mutually exclusive activity of 
the TF (B) governing the alternative cell fate acquisition. b. The deletion of the TF (A or B), that 
maintains the cell identity, is not sufficient to induce the alternative cell fate, because of internal 
cross regulatory mechanisms. c. The deletion of the TF (A or B), that maintains the cell identity, 
does not lead to the acquisition of the alternative cell fate, because the networks depending from A 
and B do not intersect.  
(From Holmberg and Perlmann, Nature Reviews Genetics 2012) 
 
5.2 Epigenetics and cell fate acquisition 
5.2.1 Basic notions of epigenetics 	
Eukaryotic DNA is wrapped around nucleosomes, multiprotein complexes composed by 
eight histone subunits: two histones 2A (H2A), two H2B, two H3 and two H4. The 
complexes of DNA with nucleosomes and other DNA-bound proteins constitute 
chromatin. When chromatin is in a closed conformation and is not accessible for instance 
to TFs binding, it is called heterochromatin, whereas in an open conformation is called 
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euchromatin. As written above the term epigenetics comprises all the inheritable 
modifications to DNA, but not in its sequence, and to the nucleosomes.  
Up to date several post translational modifications of histone tails have been identified, 
including: phosphorylation, acetylation, ubiquitination, and sumoylation. These “histone 
marks” constitute a chromatin signature drawn and recognized by specific epigenetic 
remodellers and adaptors whose binding influences the chromatin structure itself, gene 
transcription and DNA replication. Among the major epigenetic modifiers, Polycomb 
group (PcG) and Trithorax group (TrxG) protein complexes have been characterized.  
These two complexes were discovered as the causative agents, when mutated, of the 
transformation of one Drosophila melanogaster (D. melanogaster) body segment into 
another (i.e., homeotic transformation)24-26. During development the identity of each D. 
melanogaster body segment is specified by the spatial and temporal expression pattern of 
Homeobox genes (HOX genes), determined by maternal and zygotic TFs that, however, are 
present only during the early stages. At later time points only PcG and TrxG preserve the 
memory of HOX genes transcriptional states, by depositing specific histone marks. Hence 
their perturbation leads to homeotic transformations. 
PcG proteins are mainly transcriptional repressors responsible for the trimethylation of the 
lysine 27 of histone H3 (H3K27me3), in the case of the Polycomb repressive complex 2 
(PRC2) and for the ubiquitination of the lysine 119 of histone H2A (H2AK119ub,) in the 
case of Polycomb repressive complex 1 (PRC1). On the other side, TrxG proteins deposit 
an activating mark, methylating the lysine 4 of the histone H3 (H3K4me1, H3K4me2, 
H3K4me3).  
The epigenome and, consequently, the transcriptome of a cell define its identity. Indeed the 
epigenetic configurations at enhancers (i.e., genomic sequences, proximal or distal with 
respect to the transcription start site (TSS), recognized by specific TFs, which positively or 
negatively modulate gene transcription) and promoters, highly influenced by TrxG and 
PcG proteins, regulate gene expression27,28. In particular, H3K4me3 has been found to be 
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associated with active gene promoters, while H3K27me3 with repressed ones. H3K4me3 
and H3K27me3 are co-present in promoters of developmental regulator genes, allowing 
low mRNA transcription. This specific epigenetic configuration, called bivalent chromatin 
domain29, has been discovered in ESCs and confers plasticity to cells: during lineage 
specification, if the trimethylation of H3K27 is removed, the gene is activated. On the 
contrary, if H3K4me3 is erased the gene is permanently silenced. 
Also enhancers can be classified on the basis of the different TrxG and PcG epigenetic 
marks distribution. In particular the presence of only H3K4me1 characterizes the 
enhancers primed for activation and the co-presence of H3K4me1 and H3K27me3 defines 
the poised enhancers. In the latter configuration if the H3K27me3 mark is replaced by 
H3K27 acetylation the enhancer is considered active, whereas if only the H3K27me3 is 
present the enhancer is silenced. TrxG and PcG are therefore antagonistic epigenetic 
remodellers, finely tuned during development and differentiation.  
 
5.2.2 Polycomb group Proteins 
 
The catalytic components of the PRC1 are RING1A and RING1B, the E3 ubiquitin ligases 
responsible for the deposition of the H2AK119ub, an epigenetic mark linked to chromatin 
compaction and transcriptional repression. RING1A and RING1B were found to be 
associated with different components, forming the canonical and noncanonical PRC1 
complexes. In the canonical complex they associate with CBX, which allows the 
recruitment of PRC1 to specific targets marked by H3K27me3, making the chromatin 
binding PRC2-dependent30 and with BMI1, which is fundamental for the complex 
formation and activity31. On the contrary noncanonical PRC1 complexes contain RYBP 
and bind to chromatin in a PRC2-independent manner32. 
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The catalytic subunits of PRC2 are instead EZH2 or its homolog EZH1 that through their 
SET domain deposit the H3K27me3 mark. EED and SUZ12, two components of PRC2 
complexes, support the catalytic activity of EZH2/133. The binding of PRC2 complexes is 
modulated by RBAP46/48, responsible of nucleosome recognition34 and JARID2, that is 
also both a binding partner and a substrate for PRC2 itself35,36. In D. melanogaster specific 
genomic sequences responsible for PRC2 binding have been identified and named 
Polycomb responsive elements (PRE). To date an equivalent of PRE has not been 
identified in mammals. However, recently, unmethylated CpG islands associated with 
silenced enhancers have been suggested as PRC2 recruiting sites37. 
 
5.2.3 Trithorax group Proteins 
 
The first H3K4 mono-, di- and trimethylation enzyme was reported in Saccaromices 
cerevisiae (S. cerevisiae): the SET domain-containing 1 (Set1)38. To be functional Set1 has 
to be part of the COMplex of Proteins ASSociated with Set1 (COMPASS) and it is SET 
the domain that possesses the catalytic methylating activity. TrxG proteins, as mentioned 
before, were discovered in D. melanogaster thanks to homeotic transformation observed 
when they were mutated. In the fly, differently from S. cerevisiae, three H3K4 methylases 
are present: the homolog of Set1-COMPASS, the trithorax COMPASS-like and the 
trithorax-related COMPASS-like complex.  
Similarly to PcG, TrxG complexes in D. melanogaster recognize a specific sequence in the 
genome: the TrxG responsive elements (TRE). As for PRE, up to date this type of 
sequence has not been found in mammals. 
Because of the gene duplication that occurred during evolution, each complex acquired 
two paralogs in mammals39-43. The Set1-COMPASS can contain either SET1A (also 
known as KMT2 histone-lysine N-methyltransferase 2F (KMT2F)) or SET1B (also known 
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as KMT2G). The catalytic protein present in the COMPASS-like complex can be MLL1 
(also called KMT2A) or MLL2 (also known as KMT2B, MLL4, TRX2 and WBP7), while 
in the case of trithorax-related complex the methylating protein can be MLL3 (also called 
KMT2C) or MLL4 (also known as KMT2D, MLL2 and ALR) (Figure 6). To avoid 
misunderstanding, from now on KMT2B will be referred as MLL2 and KMT2D as MLL4. 
The three different COMPASS sub-classifications have some shared and some specific 
components (Figure 6). WDR5, ASH2, RBBP5 and DPY30 (WARD) are the four proteins 
falling into the commonly found components of all KMT2 complexes that function as 
complex stabilizers and enhancers of KMT2 activity44,45. Set1-COMPASS complexes 
associate specifically with WDR82 and CFP1 (CXXC finger protein 1), the trithorax 
COMPASS-like complexes with MENIN and the trithorax-related COMPASS-like with 
UTX, PTIP, PA1 and NCOA6.  
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Figure 5: The COMPASS complexes in yeast, D. melanogaster and Human 
In yeast only one COMPASS complex is present, while D. melanogaster has three COMPASS 
complexes. The components with the methylase activity in Drosophila are: SET1A, Trithorax and 
Trithorax-related. During the evolution each of them acquired two homologs. Grey subunits are 
shared among all complexes. In green the specific subunits for the trithorax-related COMPASS-
like complexes, in purple the specific subunit of trithorax COMPASS-like complexes, while in blue 
the subunits of SET1-COMPASS complexes. (From Mohan et al., Nature Reviews Cancer 2010) 					
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5.2.4 Functions and localization of Trithorax group Proteins 
 
SET1A and SET1B are the two trithorax members responsible for the majority of H3K4 
methylation46. In particular, as their ancestor Set1 in Caenorhabditis elegans, SET1A and 
SET1B can catalyse mono-, di-, and trimethylation (H3K4me1, H3K4me2 and 
H3K4me3)47. As mentioned before their specific components are WDR82 and CFP1. 
WDR82 is fundamental for proper H3K4 methylation upon H2B monoubiquitination46 and 
it associates with the phosphorylated (on serine-5 of the C-terminal domain) Polymerase II 
allowing the co-transcriptionally deposition of H3K4me348. On the contrary, CFP1 guides 
SET1A and SET1B binding to unmethylated CpG islands. Hence these two methylases 
preferentially associate with promoters and TSS (Figure 7). In the WDR82-dependent 
binding they are recruited after transcription has initiated49 as their counterpart Set1 in C. 
elegans48, whose deletion, indeed, leads to modest variation in the yeast transcriptome50. In 
the alternative case, their transcription-independent recruitment could most likely influence 
transcription. 
MLL1 and MLL2 are able to mono-, di-, and trimethylate (even if at a lower rate) H3K4 as 
SET1A and SET1B47, but they have a restricted set of targets (i.e., MLL1 is responsible for 
the trimethylation of  less than 5% H3K4 trimethylated promoter genes51). Both MLL1 and 
MLL2 can bind to promoters-associated unmethylated CpG islands through the CXXC 
domain, a type of zinc finger, whereas they can also be recruited to enhancers through the 
interaction with specific TFs (Figure 7)52,53,54. Moreover MENIN, their exclusive 
component, is the subunit that is mainly responsible for the interaction between TFs and 
trithorax COMPASS-like complexes. In particular MENIN is a tumor suppressor gene, 
which favours MLL1 and MLL2 localization at their most known targets, such as HOX 
genes43,55-57. Indeed mice knock-out for the Mll1 SET domain are viable, but show an 
impairment in Hox expression58. Hence, differently from SET1A and SET1B, MLL1 and 
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MLL2 are recruited exclusively before transcription has initiated and they can actively 
influence gene expression.  
MLL1 and MLL2 are cleaved by taspase 1, which creates an N-terminal fragment 
containing the phenylalanine and tyrosine-rich region FYRN (phenylalanine and tyrosine-
rich N-terminal) and a C-terminal fragment containing both FYRC (phenylalanine and 
tyrosine-rich C-terminal) and the highly conserved SET domain (Figure 8)59,60. FYRN and 
FYRC heterodimerize to generate a functional complex. Indeed taspase deficient mice 
present homeotic transformation61.  
MLL2 augments in vitro chromatin transcription, only if S-adenosyl-methionine (SAM), 
the co-substrate of methylation, is present, directly linking the enhancement of 
transcription to H3K4 methylation62. Moreover the MLL2-deposited H3K4me3 prevents 
H3K27me3 deposition63,64 and CpG methylation, playing an anti-silencing role65. 
MLL3 and MLL4, instead, are mostly monomethylases47 that preferentially bind to 
enhancers (Figure 7)66,67. PTIP and NCOA6, the MLL3 and MLL4 specific subunits, 
interact with the PAX family of TFs and nuclear receptors42,68,69, while CFP1 (CXXC 
finger protein 1) recruits Set1-COMPASS complexes to unmethylated CpG 
dinucleotides70. Since UTX, one of the demethylases of H3K27me3, is a component of the 
trithorax-related COMPASS-like complexes68, the monomethylation of H3K4 occurs 
concomitantly with the removal of H3K27 methylation71. Afterwards P300/CBP is 
recruited to acetylate H3K27. The co-occurrence of H3K4me3 and H3K27ac, as 
aforementioned, is a signature of an active enhancer. 
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Figure 6: Functions and localization of KMT2 proteins 
Schematic representation of KMT2 binding. KMT2C and KMT2D (MLL3 and MLL4), mostly 
bind at enhancer (through the interaction with TFs) and are responsible for H3K4me1. KMT2F and 
KMT2G (SET1A and SET1B) are the main responsible for H3K4 trimethylation at promoters. 
They can interact with TFs, with RNApolII and with CpG islands through the CFP1 subunit. 
KMT2A and KMT2B (MLL1 and MLL2), instead, can bind both to promoters (through their 
CXXC domain or through the interaction with TFs) and to enhancers (through the interaction with 
TFs) and deposit mostly the H3K4me3 mark.  
(From Rao and Dou., Nature Reviews Cancer 2015) 
 
 
 
Figure 7: Protein domains of KTM2 enzymes 
The specific and shared protein domains are depicted. In particular KMT2A and KMT2B (MLL1 
and MLL2) possess a taspase cleavage site. Upon taspase cleavage the two protein fragments form 
a heterodimer through FYRN and FYRC, in order to be functional. In pink the catalytic SET 
domain. 
(Adapted from Rao and Dou., Nature Reviews Cancer 2015) 
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5.2.5 Trithorax group Proteins and redundancy 
 
In the case of TrxG genes, evolution corresponds to gene duplication. This on one side is 
synonymous with redundancy, but on the other side it increases the level of complexity and 
specification of H3K4 methylation deposition by each COMPASS member. Despite gene 
duplication, some specific and non-redundant functions still pertain to each trithorax 
member. Indeed the single knock-out mice for Mll1 and Mll2 are embryonic lethal, 
pointing to the absence of a complete compensation among the two paralogs55,56.  
Moreover, although the components composition and the protein domains are the same in 
each of the three sub-classifications (Figure 8), they display different subnuclear 
localizations72,73. In the current view each TrxG protein has a specific role, which is 
temporally and spatially modulated. Mll2 represents a clear example, since it is 
fundamental during gastrulation until day E.8.5/9.5 of gestation64. Only the deletion in this 
time frame results in embryonic lethality. Then, MLL2 is again essential during 
oogenesis74 and spermatogenesis64. 
Mll1, instead, is required later during development, especially for the hematopoietic 
lineages acquisition75. 
Moreover during in vitro retinoic acid (RA)-ESC differentiation, MLL1 and MLL2 
regulate different Hox clusters76.  
Recently, MLL2 has been found to be required for H3K4me3 deposition on bivalent 
promoters in ESCs while MLL1 is redundant76,77. 
Hence, these two paralogs present non-redundant activities, regulated spatially (i.e., they 
are the main H3K4 methylases of specific cell types and they have specific targets) and 
temporally (i.e., they are fundamental in specific developmental time frames). 
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5.2.6 Trithorax group Proteins, cell cycle and cell mortality 
 
TrxG proteins regulate and are regulated by the cell cycle. MLL1 presents a biphasic 
expression: it peaks during G1-S and G2-M transitions and it is degraded during late S and 
M phases by respectively the E3 ubiquitin ligase SCF bound to S-phase kinase-associated 
protein 2 (SCFSKP2) and by the anaphase-promoting complex bound to its coactivator 
CDC20 (APC/CCDC20) (Figure 9)78.  
MLL1, however, remains bound to DNA during replication and mitosis, such as its fly 
homolog Trx, preserving the transcription of cell-cycle genes and maintaining histone 
marks in the newly assembled nucleosomes79,80 (Figure 9). Since an epigenetic 
modification is inheritable by definition, this observation makes the H3K4me3 a bona fide 
epigenetic mark. The turnover of other MLL proteins has not been investigated yet. 
In the case of DNA damage, the phosphorylation on serine 516 of MLL1 reduces its 
degradation by SCFSKP2 81. Consequently H3K4me3 deposition at late replication origins 
increases, impeding the binding of CDC45, a component of the pre-replication complex, 
and therefore the replication of the damaged DNA (Figure 9). 
 
 
 
Figure 8: Cell cycle dependent degradation of MLL1 
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MLL1 is degraded during late S and M phases, while it peaks at the G1/S and G2/M transitions. 
MLL1 remains associated to chromosomes during mitosis and replication. In case of DNA damage, 
MLL1 phosphorylation of serine 516 reduces its degradation, increasing the H3K4me3 deposition 
at late origins and inhibiting the binding of CDC45. This impedes the replication of damaged DNA. 
Moreover both MLL1 and MLL2 interact with E2F proteins regulating the cell cycle. 
(Adapted from Schuettengruber et al., Nature Reviews Molecular Cell Biology 2011) 
 
On the other side, in the presence of DNA damage, one of the targets of MENIN-
containing complexes is p21, the primary downstream effector of p53, and p1682.  
In the absence of damage, cell cycle regulator genes, such as p27 and p18 are 
transcriptionally switched on by MLL1 and MLL2 COMPASS-like complexes in 
fibroblasts83. Furthermore these complexes modulate also the expression of cyclin 
dependent kinase inhibitors (CDKI)82 and of cyclins61. 
Moreover multiple cell types Mll2-/- present a higher cell death rate than the controls. Mll2-
/- embryos die before E.10.5 due to a growth retardation that culminates in a high cell 
death56. Mll2-/- ESCs show a higher apoptotic rate than wild-type (wt) controls, likely due 
to Bcl2 down-regulation, while cell cycle length and cell cycle phases distribution are not 
affected84. If Mll2 is deleted in 2 months-old male mice, this results in infertility associated 
with an increase apoptosis of spermatogonia64. Finally if Mll2 is conditionally knocked-out 
in oocytes, pro-apoptotic genes, such as Bax, Casp6 and Setd7, which stabilizes p53, are 
up-regulated74.   
MLL1 and MLL2 associate also with cell-cycle regulatory TFs as E2F to regulate G1-
phase cell cycle genes85. Moreover the two proteins modulate different E2F genes 
suggesting again their non-redundancy. 
Cellular senescence is associated with the activation of p16, whose H3K4 trimethylation 
increases during cellular ageing, counteracting the role of PcG proteins,82 fundamental in 
young cells55,86. 
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5.3 Transdifferentiation 
5.3.1 Models of TF mediated cell reprogramming and conversion 
 
TFs that drive cell fate change frequently are terminal selector genes in the resultant cell.  
Four models have been proposed to describe how a TF can start the process of lineage 
conversion87. In the first case (Figure 5a), despite the fact that the promoters of the genes 
important for transdifferentiation or reprogramming are in an epigenetically closed 
configuration, their enhancers are accessible to the TF. The TF binding can induce 
chromatin remodelling at the promoter, and subsequently the activation of 
transdifferentiation/reprogramming effector genes. The majority of polycomb targets, the 
genes trimethylated at H3K27, have exactly this configuration88. 
Pioneer factors, instead, are able to bind also to closed chromatin, displacing the 
nucleosomes and recruiting other chromatin modifiers and TFs thus initiating the process 
of cell conversion (Figure 5b). 
In other cases the TF can access its binding sites stochastically, for example during their 
temporary unwinding from the nucleosome or during nucleosome turnover (Figure 5c). 
During cell division, instead, there could be a time window in which the repressive marks 
are still not re-deposited and therefore the TF could bind (Figure 5d). 
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Figure 9: Models of reprogramming/transdifferentiation TF-binding  
a. If the enhancer is in a permissive configuration the TF can bind, triggering chromatin 
remodelling at the promoter. b. Pioneer factors are able to bind to chromatin even if it is in a close 
conformation, leading to its subsequent remodelling. c. In the stochastic model TFs can bind to 
chromatin for example when, by chance, a specific sequence becomes accessible upon temporary 
nucleosome shifting. d. During cell division nucleosome are displaced and the new ones are 
initially not modified, giving to the TF a time window opportunity for binding. 
(From Vierbuchen and Wernig, Molecular Cell 2012) 	
	
	
	
5.3.2 Neuronal transdifferentiation 
 
In 2002 the group of Götz reported one of the first cases, in literature, of neuronal 
transdifferentiation89. They showed that the forced expression of Pax6 in astrocytes, one of 
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the main drivers of neurogenesis in vivo, orients them towards neuronal fate. Subsequently, 
other works demonstrated that astrocytes can be converted into neurons also through the 
expression of different genes, such as Ngn290. In these protocols, however, both the 
original cell and the transdifferentiated resultant derive from ectoderm. 
In 2010 Wernig and colleagues screened 19 genes for their ability to induce cell 
conversion of mouse embryonic fibroblasts (MEFs) into neurons, hence cells deriving 
from two completely different germ layers91. Criteria for including genes were their 
neuronal expression and their role in neural development and in the reprogramming to 
pluripotency.  
They showed that the combination of three TFs, Brn2, Myt1l and Ascl1 (BAM pool), was 
able to transdifferentiate MEFs (ca. 20% efficiency) and mouse tail tip fibroblasts (ca. 6% 
efficiency) into functional neurons (i.e., able to fire action potential and to form synapses) 
in 14 days. They named the transdifferentiated cells induces Neuronal cells (iNs) to 
distinguish them from induced neurons (i.e., brain-derived cells). Also the BAZ pool, in 
which Mytl1 was replaced by Zic1, was efficient in MEFs transdifferentiation, but BAZ-
iNs presented a less complex morphology.  
When they functionally and morphologically analysed BAM-iNs, they observed that the 
majority of them were excitatory, expressing vGLUT1 and Tbr1, markers of cortical 
excitatory neurons and that, if co-cultured with astrocytes, iNs released excitatory post-
synaptic currents (EPSC). Only a small fraction of iNs, instead, expressed GAD, a 
GABAergic marker and no inhibitory post-synaptic currents (IPSC) were recorded. 
Hence, Wernig and colleagues demonstrated that cells deriving from the mesoderm can 
transdifferentiate into cell deriving from the ectoderm, implying that the BAM pool can 
drive a conspicuous and efficient epigenetic remodelling.   
Just a year later, the same group demonstrated that also hepatocytes, deriving from 
endoderm, upon BAM pool transduction, transdifferentiate into functional iNs with an 
efficiency similar to that of tail tip fibroblasts92.  
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Once the new cell identity is well-established, a fully transdifferentiated cell should 
become independent from the driver instructor factor(s). BAM genes were administered 
through lentiviral vectors, whose expression was induced and sustained by doxycycline 
(dox) administered in the medium throughout the protocol. They indeed showed that 5 
days of dox administration was enough to generate both hepatocytes- and MEF-iNs, even 
if at a low percentage92. Removing dox 11 days after transduction did not change 
transdifferentiation efficiency at 22 days. This is likely due to the up-regulation of the 
endogenous levels of Ascl1, Brn2 and Myt1l genes. At day 11-12 Ascl1 reaches a plateau, 
while the levels of Brn2 and Myt1l increase continuously until day 24. 
 
5.3.3 Human induced neuronal cells 
 
When Wernig and colleagues used the BAM pool to transdifferentiate human fetal 
fibroblasts into neurons, they observed β-III tubulin-positive (Tuj1+) cells after 7-10 days, 
but these human iNs appeared functionally immature93. Adding NEUROD1 to the pool, 
they finally succeeded in the generation of firing action potential iNs, that, like mouse iNs, 
were mostly excitatory. However the efficiency of conversion remained low (ca. 2-4%, 10 
time less than MEFs) and transdifferentiation lasted around 35 days. Similar results were 
obtained using the five factors effective in mouse (5F pool: Brn2, Olig2, Ascl1, Myt1l, 
Zic1)91,94.  
Alternatively miR-9/9* and miR-124 alone, specifically expressed in postmitotic neurons, 
were used as factors to transdifferentiate human fibroblasts, but the resulting iNs were 
functionally immature95. If NEUROD2, ASCL1 and MYT1L were added to the miRNA, 
they acted synergistically: transdifferentiation efficiency increased and iNs were 
functional. Moreover also the combination of miR-124, BRN2 and MYT1L led to neuronal 
transdifferentiation, even if iNs generated presented less competent synapses96.   
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In all the aforementioned reports, however, iNs were composed of a mixed population.  	
5.3.4 Disease modelling using iNs 	
In the case of 5F pool-iNs, the starting population consisted of fibroblasts derived from 
control and patient with Familial Alzheimer’s Disease (FAD), carrying a PSEN mutation. 
FAD-iNs presented a disease-specific phenotype, showing amyloid precursor protein 
(APP) puncta in endosomes, rescued by the wt expression of PSEN194. This was the first 
demonstration that, when affected cell types, such as neurons, are not easily accessible, 
transdifferentiation can be exploited with the purpose of disease modelling.  
Another proof of principle that transdifferentiation can be exploitable to model disease 
came from Südhof’s laboratory. They showed that the transdifferentiation of MEFs with 
the autism-related neuroligin-3 mutation is not affected, but that mutated iNs resemble in 
vivo affected hippocampal neurons. Indeed, mutated iNs present a reduction in the surface 
level of AMPA receptors with the consequent decrease of miniature EPSC both in 
amplitude and in frequency. This suggests that, even though the process of 
transdifferentiation does not follow the canonical physiological differentiation path, the 
resulting neurons are comparable to the primary ones97.  
To model disease and to study development, many successful attempts have been made to 
transdifferentiate fibroblasts into specific neuronal types involved in pathologies, such as 
dopaminergic neurons for Parkinson’s disease. Pfisterer and colleagues demonstrated that 
the addition of LMX1a and FOXA2 to BAM factors was effective for the 
transdifferentiation of human fetal fibroblasts into dopaminergic iNs (purity: 25% of all 
iNs generated)98. A higher purity was reached using the combination of Ascl1, Nurr1 and 
Lmx1a, effective both for mouse and human fibroblasts (efficiency 18%; purity 85% and 
60% of iNs were dopaminergic, in mouse and human respectively)99. However the 
transcriptome of dopaminergic iNs was different from bona fide dopaminergic neurons. 
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Alternatively Ascl1, Pitx3, Lmx1a, Nurr1, Foxa2, En1, SHH and FGF8 were used to 
generate iNs, which in this case were also able to compensate for the absence of dopamine 
in vivo100. Despite the usage of eight TFs and their effectiveness when transplanted, the iNs 
gene expression profile was still different from the one of dopaminergic neurons. 
Another fundamental type of neurons is constituted by motor neurons. Through the 
combination of BAM factors with Lhx3, Hb9, Isl1 and Ngn2  (and NEUROD1 for human 
fibroblasts) mouse and human fibroblasts were transdifferentiated into motor neuron 
iNs101. iNs expressing the mutated gene SOD1, that causes amyotrophic lateral sclerosis 
(ALS), phenocopied the disease-survival defects of affected motor neurons. 
These are only some examples of transdifferentiation towards specific neuronal types. A 
perfect combination of factors for the generation of iNs that fully recapitulate (by their 
function and their expression profiles) in vivo neurons has not yet been discovered. These 
studies can anyway give more insights on neuronal development and on the role of the TFs 
used for transdifferentiation. iNs, however, remain a promising, but still perfectible, tool to 
study disease-affected neurons. When the right “factors cocktail” will be found, hopefully 
in the near future, iNs could be exploited in regenerative medicine. With this purpose non-
integrative transdifferentiation protocols, such as transfection of the factors with 
poly(amidoamine)102 and adenoviral gene delivery103, have been established. Since iNs are 
not expandable and the efficiency of transdifferentiation of human fibroblasts is low, 
protocols have been adapted to overcome these limitations. With the usage of small 
molecules inhibiting glycogen synthase kinase-3β and SMAD signaling, MEF-to-iNs 
conversion, driven by ASCL1 and NGN2, increases up to 200%104. Alternatively, 
transdifferentiation towards expandable induced neural precursor cells (iNPCs), prior to 
iNs, was achieved to overcome limitation on abundance105.  
 
		 42	
5.3.5 How the BAM pool works 	
BAM factors act synergistically for the generation of iNs, inducing a conspicuous 
transcriptome remodelling: 2522 genes are differentially expressed between MEFs and 
iNs106. The resetting of the transcriptome should reflect a major restructuring of the 
epigenome; however, to date, no data are present on how the epigenetic landscape changes 
in iNs and on how BAM factors guide this remodelling. 
If the MEFs-to-iNs transdifferentiation system were to be classified in the aforementioned 
four TFs-mediated reprogramming systems, it would fall in the “immediate access” 
category. ASCL1 is in fact a pioneer factor that can immediately bind chromatin leading, 
in a 5F pool transduced MEFs, to the first Tuj1+ (Neuronal- specific Class III β-tubulin) 
cells appearance already 3 days after infection91. In particular ASCL1 functions as a 
transcriptional activator, recognising a newly discovered epigenetic mark: the trivalent 
chromatin state, characterized by the co-presence of the H3K4me1, the H3 lysine 9 
trimethylation (H3K9me3) and the H3K27 acetylation (H3K27ac)106. Accordingly, it has 
been demonstrated that cell types with an enrichment of the trivalent chromatin state have 
a higher transdifferentiation efficiency. Moreover cell proliferation is dispensable for the 
occurrence of direct cell conversion. One day after transgene induction only a minority of 
cells still proliferates91 and blocking DNA replication does not affect the appearance of 
iNs107. Single cell RNA-sequencing (RNA-seq) of MEFs Ascl1-transduced, showed that 
upon transgene induction the switched-off or down-regulated genes are the ones linked to 
mitosis, confirming that cell division is not required for transdifferentiation108. In parallel 
ASCL1 up-regulates genes associated to cytoskeletal reorganization, synaptic activity and 
neurite extension, confirming its essential role throughout transdifferentiation108. 
Zfp238, a transcriptional repressor whose expression increases upon BAM pool dox-
induction, was discovered as one of the main targets of ASCL1106. When Zfp238 is 
expressed in combination with Myt1l and other neuronal TFs up-regulated during 
		 43	
transdifferentiation (i.e., Rfx1, Lmo2 and Tcfl5) it induces the formation of neuronal-like 
structures in MEFs, without the need of the expression of ASCL1. Hence Zfp238 is one of 
the key effectors of ASCL1.  
Interestingly, a portion of MEFs infected with Ascl1 alone does not become iNs and 
activates the myocyte transcriptional program, while concomitantly down-regulating 
Ascl1108. This transcriptional deviation is however blocked in the presence of BRN2 and 
MYTL1L. Moreover, iNs at day 22, transduced only with Ascl1, fail to mature and mostly 
acquire the myogenic expression profile. Hence BRN2 and MYT1L present a major 
involvement in neuronal maturation in later stages of transdifferentiation106,108. It is 
ASCL1 that recruits BRN2 to some of its targets, otherwise not accessible, confirming its 
role as pioneer factor106.  
The definition of transdifferentiation excludes the passage through the pluripotent state. In 
the case of neuronal transdifferentiation this has been so far ruled out because of the 
rapidity of appearance of Tuj1+ cells and of the absence of cells positive for pluripotency 
markers91. Recently it has been shown that during the first phases of MEFs conversion, 
their transcriptome clusters with the one of NPCs108. Then, as soon as iNs maturation 
progresses, their expression signature detaches from the one of NPCs and gets closer to the 
one of iNs108.  However the two main NPC markers, Sox2 and Pax6, are never induced 
during the process, implying that MEFs pass through an intermediate stage that only 
resembles NPCs.  
All transduced MEFs are equally competent for the activation of the transdifferentiation 
program: the transcriptional analysis of starting MEFs does not show the presence of 
subgroups that could be less or more prone to cell conversion. Infected MEFs 
homogenously induce Ascl1-targets and silence MEF-genes108. Hence the 20% efficiency 
should be ascribed to the aforementioned silencing of Ascl1 and activation of myogenic 
pathway, but the reason why this occurs only in some cells remains unknown. 
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5.3.6 PcG, TrxG and transdifferentiation 
 
In certain species transdifferentiation occurs physiologically during both development 
and/or regeneration. For instance, the lens of the newt regenerates through the 
transdifferentiation of pigmented epithelial cells. As stated earlier, this entails a fine-tuned 
balance between plasticity and cell identity stability. To allow the cell to change fate, the 
activation of target cell genes and the repression of starting cell ones are essential. Hence 
the orchestrated activity of TrxG and PcG proteins is likely to be one of the main drivers.  
In D. melanogaster each imaginal disc, a fly larval developmental structure, gives origin to 
a specific segment with a cuticular structure. The pre-determined imaginal disc clusters of 
cells can transdifferentiate during regeneration, upon the ectopic expression of morphogens 
and in the case of deregulation of PcG genes. Hence PcG proteins have a role in the 
suppression of the alternative cell fate acquisition, as demonstrated for the homeotic 
transformations. Fly cells, during regeneration, down-regulate PcG through the c-Jun N-
terminal kinase (-) pathway and PcG mutant flies show a higher rate of 
transdifferentiation109. If transdifferentiation is artificially induced, members of the PcG 
and the TrxG families change their expression, and when some of them are mutated, 
transdifferentiation frequency is increased110. Hence, in D. melanogaster, the two families 
of histone methylases are the guardians of the cell fate identity that is not however, 
irreversibly crystallized.  
In C. elengans, during development, a specific hindgut cell (i.e., the Y cell) physiologically 
transdifferentiates to form a motor neuron. Mutations of the demethylase of H3K27, 
Jmjd3-3.1, and of the ortholog of Set1-COMPASS complex, Set-2, lead to 
transdifferentiation defects111. Moreover C. elegans germ cells knock-out for PRC2 show a 
higher rate of TF-mediated transdifferentiation toward both neurons and muscle cells112. 
Hence, also in C. elegans, the two antagonistic families play a major role during 
transdifferentiation and the preservation of cell identity. 
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Furthermore some of the TFs that drive, in mammals, in vitro transdifferentiation (e.g., 
MyoD1, Cebpa, Pdx1, etcetera) are repressed by H3K27me3 in the starting cell while they 
are active in the resultant cell, pointing to the role of PcG proteins in the silencing of 
terminal selector genes of other cell identities113.		
5.3.7 Histone methylation and corticogenesis 
 
In the currently accepted model of corticogenesis, epigenetics plays a major role114. Radial 
glia (RG) cells, specific neural stem cells that reside in the ventricular zone, either directly 
or indirectly (through the generation of basal progenitors (BPs)) give rise to cortical 
neurons and only later to glia. The six cortical layers are generated in a temporally 
programmed fashion as well.  It has been demonstrated both in vitro and in vivo that at 
each time point neural progenitors are “committed” to generate defined neurons in a 
largely cell-autonomous manner115-117. The sequential modification of the epigenetic 
profile of the RG cells could be responsible for the acquisition of their different 
differentiation potential. One of the most attractive hypotheses is the presence of a 
repressor, which is down-regulated during RG cell cycles, leading to the derepression of 
targets relevant for the differentiation into that time-specific cell type. Ezh2 shows indeed 
this expression pattern: it is down-regulated both along the 11 cell cycles of RG cells and 
during neurons generation118. However, the ablation of this enzyme through different 
methods in vivo led to interestingly opposite results118,119, further underscoring the 
importance of precise timing in the execution of its molecular function. Moreover the 
highly dynamic H3K27 methylation mark during neuronal differentiation in vitro120 and 
the aforementioned theory of progressive Polycomb target derepression in the RG suggest 
a role for one of the main H3K27 demethylating enzymes, JMJD3. Our group has already 
demonstrated that this demethylase is fundamental for neural lineage commitment121 and is 
		 46	
also currently unravelling its role during corticogenesis in vivo with the generation of 
constitutive and conditional knock-out mice122. 
Conversely, the role of H3K4me3 is less well understood, but it has been still associated 
with neurogenesis. It has been recently shown in C. elegans that the Set1 complex 
participates to the process of dedifferentiation of the hindgut cells that will subsequently 
redifferentiate in motor neurons111. 
MLL1 and MLL2 have been shown to be essential in neural commitment. Indeed the 
differentiation of Mll1-/- Subventrincular Zone Neural stem cells (SVZ NSCs) into neurons 
is impaired, while their proliferation rate is not altered123. This deficit is not attributable to 
a reduced trimethylation at MLL1 targets because the level of H3K4me3 is not altered. 
This implies a possible compensation operated by the homolog MLL2. The authors 
described the absence of the erasure of H3K27me3 at important neuronal targets as the 
cause of the defect in neuronal differentiation. Furthermore it has been recently shown that 
MLL1 is essential for neural development in Danio rerio124. In particular the absence of 
Mll1 in zebrafish leads to a reduction in the proliferation of neural progenitor cells and to 
an anticipated neuronal differentiation. On the other side Mll2-/- ESCs have a severe delay 
in ectodermal in vitro differentiation84, but they are able to differentiate and they are 
positive for mature neuronal markers upon retinoic acid treatment. However, the 
expression of maturation genes in these cells is highly affected. It has been shown recently 
that in ESCs MLL2 is responsible of H3K4 trimethylation at bivalent promoters67,76. 
During neuronal differentiation this defect is only partially overcome, also through the 
compensation of MLL1, but Mll2-/- ESCs can anyway respond to retinoic acid 
treatment67,76. Moreover the Mll2 deletion in the excitatory neurons of the forebrain 
impairs both short and long term memory125. 161 genes have been found to be 
differentially expressed in Mll2-/- dorsal dentate gyrus with respect to controls by 
microarray analysis. The majority of them are down-regulated and linked to memory 
formation and neuronal plasticity. The levels of H3K4me3 and H3K4me2 it these genes 
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are reduced, as assessed through Chromatin Immunoprecipitation coupled to detection by 
quantitative real-time PCR (ChIP-qPCR), further defining them as MLL2 targets and 
excluding the compensation by other TrxG proteins. However, surprisingly, Mll2-/- brains 
and neurons do not present an altered morphology.  
Hence, despite the fact that Mll1 and Mll2 arise from gene duplication56,126,127 and share the 
classical Trithorax core components, plus specific components such as MENIN and 
HCF1O, they have precise and non-replaceable roles during neuronal differentiation. 
 
5.4 Aim of the thesis 
 
The aim of this study is the characterization of the role of MLL1 and MLL2 during BAM 
factors-driven MEFs-to-iNs transdifferentiation. This protocol offers three main 
advantages: i) it fosters the transition between cell lineages that derive from different germ 
layers, therefore requiring the transition across a “high epigenetic hill”; ii) it allows the 
complete erasure of the MEF epigenetic signature and the establishment of the neuronal 
one; iii) it is a remarkably efficient and fast process. Hence this system is appropriately 
suited for investigating how a massive TF-mediated epigenome resetting occurs at the 
molecular level. Moreover BAM factors are fundamental during physiologic neuronal 
differentiation, but it is unclear how they coordinate the massive epigenetic remodelling 
which occurs during direct cell conversion and what are the epigenetic remodellers with 
which they cooperate to achieve the complete epigenome restructuring. On this perspective 
we decided to unravel whether and how MLL1 and MLL2 are relevant during 
transdifferentiation, since they actively participate to both in vivo and in vitro neuronal 
differentiation. This will allow first to dissect a possible involvement of these two 
methylases during transdifferentiation process per se. Furthermore it will give more 
insights on their role during neuronal specification.  
		 48	
6. MATERIALS AND METHODS 
6.1 Mouse Models 	
- Conditional knock-out for Mll: mouse models used in this study were conditional knock-
out for Mll1128, for Mll256 or for both. In these mice the exon 2 of Mll1 or/and Mll2 gene 
was flanked by two LoxP sites and the mice also harboured the ROSA26-CreERT2 allele to 
enable tamoxifen-induced Cre-mediated recombination. They were crossed with mice 
presenting the YFP in the ROSA26 locus, downstream to a stop cassette between LoxP 
sites. Hence Cre was maintained in heterozygosis, reducing its toxicity. Control MEFs 
were derived from Mll+/+YFP+Cre+ mice and in the case of Mll1 also from Mll1fl/+ 
YFP+Cre+ ones.  
- NOD SCID IL2Rγ-/- were bought from Charles River Laboratories and bred in house. 
All mice were housed and bred in a specific pathogen free (SPF) animal house. 
Mice were genotyped extracting DNA from tail biopsies. In particular tails, in 400µl of 
Lysis Buffer (100mM Tris-HCl pH 8.5, 5mM EDTA, 0.2% SDS, 200mM NaCl, 100 µg 
Proteinase K/ml), were digested at 55°C in agitation. Afterwards DNA was precipitated 
with isopropanol and washed in 70% ethanol. After ethanol evaporation, DNA was 
resuspended in ddH2O. PCR were run on TAE 1% Agarose gel (2% in the case of Mll2).  
Primers used are listed in Table 1. 
		
Table 1: Sequences of primers used for genotyping 	
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6.2 Derivation of transdifferentiation starting cells 
6.2.1 MEFs derivation  	
Embryos were harvested at E.13.5 of development. After removal of both the head and the 
liver, cells were enzymatically and mechanically dissociated. In particular, the embryo 
body was finely cut with scissor and afterwards 1ml of trypsin was added. Cells were 
incubated at 37° C, 3% O2, 5% CO2 for 30 minutes pipetting every 10 minutes. Dissociated 
MEFs were seeded in MEFs medium and cultured at 37 °C, 3% O2 and 5% CO2. 
MEFs medium: 
Dulbecco’s Modified Eagle Medium without L-Glutamine (DMEM) (Lonza, catalog 
number BE12-614F) 
10% Fetal Bovine Serum (FBS) (HyClone, catalog number SH30088.03) 
1% Penicillin/Streptomycin (Life Technologies, catalog number 15140-122) 
1% L-Glutamine 200mM (Life Technologies, catalog number 25030-024) 
1% Sodium pyruvate (Lonza, catalog number BE13-115E) 
1% Non-essential aminoacids (Lonza, catalog number BE13-114E) 
0.2% β-mercaptoethanol 50mM (Life Technologies, catalog number 31350-010) 	
6.2.2 MEFs 4-OHT treatment  	
To allow exon 2 deletion MEFs, at passage 2 maximum, were treated for 5 days with 4-
Hydroxytamoxifen (4-OHT), added to the MEFs medium in a final concentration of 
1000ng/ml, and then left either 2 or 7 days in medium not supplemented with 4-OHT. 
MEFs Mll+/+ 4-OHT-treated were used as control for MEFs Mllflox/flox 4-OHT treated, to 
rule out Cre and 4-OHT toxicity in all the experiments. However, for Mll1 ScanR 
experiments, MEFs Mll1flox/+ 4-OHT treated MEFs were used as control. 		
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6.2.3 Assessment of exon2 deletion of both Mll1 and Mll2 	
To determine the entity of Mll exon 2 deletion, TaqMan assays were performed collecting 
the MEFs the day were plated for transdifferentiation. In particular, TaqMan was executed 
on 7900HT Fast Real-Time PCR system (Applied Biosystems), analyzing each sample in 
triplicate and using Tert as housekeeping. The Primers and reporters sequences are listed in 
Table 2. 
 
Table 2: Sequences of primers and probes used for Taqman assays 
 
DNA was extracted through DNeasy Blood and Tissue kit according to manufacturer’s 
instruction (Qiagen, catalog number 69504). Briefly, cells were lysed in the appropriate 
buffer (with proteinase K added) and loaded onto the DNeasy Mini spin column. Through 
centrifugation only DNA was bound to the column. After the washing of the remaining 
contaminants, DNA was eluted in AE buffer. 
 
6.2.4 Western blot for MLL2 
6.2.4.1 Protein extraction  	
Pellets, of at least 8 x 106 cells, were collected in the day MEFs were plated for 
transdifferentiation. After washing each 15-cm dish 2 times with cold PBS, 5 ml of cold 
PBS were added and MEFs were scraped and collected in a tube maintained on ice. Cell 
suspensions were centrifuged at 4 °C, 1100 rpm for 5 minutes. The supernatants were 
removed and the pellets were immediately put in dry ice and stored in –80 °C until proteins 
were extracted. 
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When proteins were extracted, pellets were thawed on ice. 4 volumes of RIPA buffer were 
added and tubes were put at 4 °C on a rotating wheel for 30 minutes. Extracts were 
centrifuged for 30 minutes at 13000 rpm at 4 °C and supernatants were transferred in new 
tubes and store at -80 °C. 
RIPA buffer composition: 
10 mM Tris-HCl pH 8 
1% Triton X-100 
0.1% SDS 
0.1% Sodium Deoxycholate 
140 mM NaCl 
1 mM EDTA  
Before usage the protease inhibitor cocktail (PIC) (Sigma Aldrich, catalog number P8340) 
and Phenylmethanesulfonyl fluoride (PMSF) (0.5 mM) (Sigma Aldrich, catalog number 
P7626) were added. 
Proteins were quantified at the spectrophotometer (λ 595nm), through the Bradford protein 
assay as followed: 
200µl of Bio-rad protein Assay Dye reagent Concentrate 
800µl of ddH2O 
1µl of protein extract 
using BSA (NEB) do derive a standard curve. 
 
6.2.4.2 Western blot 
  
Western blot was performed loading at least 70 µg of protein extract, diluted in RIPA 
buffer plus PIC and PMSF. The NuPAGE LDS Sample Buffer (4x) supplemented with 
Dithiothreitol (DTT) (50 mM) was used (ThermoFisher Scientific, catalog number 
NP0007). After denaturation at 95 °C for 3 minutes, proteins were loaded on NuPAGE 
Novex 3-8% Tris-Acetate Proteins Gels (ThermoFisher Scientific, catalog number 
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EA0378BOX). The Novex Sharp Pre-stained Protein Standard (ThermoFisher Scientific, 
catalog number LC5800) was used as marker. Run was executed in the NuPAGE Tris-
Acetate SDS Running buffer (20X) (ThermoFisher Scientific, catalog number LA0041) at 
4°C, initially at 80 V and, when the bands started to separate, at 100 V.  
Wet transfer was performed at 4 °C, 30V with the Immobilon-P, 0.45 µm, PVDF 
membrane (Merck Millipore, catalog number IPVH00010) activated with methanol. 
Transfer buffer was prepared as followed (700ml): 
200 ml methanol 
100 ml Towbin Buffer (TB) 10X (0.25 M Tris base, 1.9 M glycine) 
dH2O to 700 ml 
The quality of transfer was checked through Ponceau staining (VWR) and after the 
washing with TBS-T, the membrane was incubated with the primary antibodies overnight 
at 4 °C. The step of blocking was performed only for the housekeeping (1h in 5% (w/v) 
skimmed milk powder in TBS-T at room temperature).  
TBS-T composition (500ml): 
50 ml TBS 10X (final concentration 25 mM Tris, 150 mM NaCl, 2 mM KCl) 
500 µl Tween-20 (final concentration 0.1%) 
dH2O to 500 ml 
The rabbit anti-MLL2 antibody was provided by Stewart Lab.56. The antibody was raised 
against amino acids 864-980. The 2 expected bands were of 284 (the full length) and 225 
(the taspase product) kDa. The anti-MLL2 antibody was diluted 1:1000 in TBS-T 3% 
BSA.  
The mouse anti-VINCULIN antibody (Sigma Aldrich, catalog number V9131) was diluted 
1:400 in TBS-T with milk (expected band 116 kDa). 
After 3 washes in TBS-T, the membrane was incubated with the secondary antibodies, 
diluted 1:10000 in 5% milk, 1h in agitation at room temperature. 
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Afterwards the membrane was washed 3 times with TBS-T and then the ECL Prime 
Western Blotting detection reagent was used (Sigma-Aldrich, catalog number 
GERPN2236). 
Images were acquire at ChemiDoc with the Image Lab Software of Bio-Rad. 
 
6.3 Transdifferentiation protocol 
6.3.1 Vector production 
 
BAM vectors were generated through calcium phosphate transfection of human embryonic 
kidney 293T (HEK293T) cells and ultracentrifugation. The following transfer plasmids, 
deposited by the Wernig Lab in Addgene, were used: 
Tet-O-FUW-Brn2; 
Tet-O-FUW-Ascl1; 
Tet-O-FUW-Myt1l; 
UbC-rtTA 
BAM vectors were produced using a third generation system (envelope plasmid: pMD2-
VSV-G; packaging plasmids: pMDLg/pRRE and pRSV-REV).  
All plasmids were extracted through the Nucleobond Xtra Maxi kit (Macherey-Nagel, 
catalog number 700414-10) according to manufacturer’s instructions. 
9x106 of HEK293T cells (harboring the mutant gene of SV40 Large T Antigen) were 
plated in a 15-cm dish in Iscove’s Modified Dulbecco’s Medium (IMDM) (Sigma Aldrich, 
catalog number I3390), 10% FBS, Penicillin and Streptomycin (25U/mL each) and 1% L-
Glutamine 200mM and incubated at 37°C, 21% O2, 5%CO2. The day after, 1h before 
transfection, medium was replaced with 22.5 ml of fresh IMDM. In the meanwhile the 
following mix was prepared: 
transfer vector: 36 µg  
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pMD2-VSV-G: 9 µg 
pMDLg/pRRE: 12,5 µg  
pRSV-REV: 6,25  µg  
0.1X TE/ddH2O (2:1) to a final volume of 1125 µl. 
Finally, 125 µl of 2.5 M CaCl2 were added to the mix and the tube was put on a rotating 
wheel for at least 20 minutes. 
DNA precipitate was obtained by drop wise addition, on vortex at full speed, of 1250 µl 
2X HBS solution (281 mM NaCl, 100mM HEPES, 1.5 mM Na2HPO4 pH 7.12, 0.22 µM 
filtered) to the 1250 µl mix previously prepared. This preparation was immediately added 
to HEK293T cells supernatant, maintaining the pipette on the medium surface, and cross 
movements were executed. 
Cells were successively incubated at 37°C, 21% O2, 5% CO2 for 14 hours and afterwards 
medium was replaced with 16 ml of fresh IMDM medium. 30 hours after medium 
changing, the supernatant was filtered through a 0.22 µm pore nitrocellulose filter and 
ultracentrifuged at 20000 rpm in SW32Ti rotor (Optima L-60 preparative Ultracentrifuge; 
Beckman) for 2 hours at 20 °C. Pellets were resuspended, without doing bubbles, in a 
volume of sterile PBS representing 1/400 of the starting medium volume. Finally vector 
was aliquoted and stored at -80°C. Usually, to have enough vector for a single experiment, 
14 15-cm dishes per vector were transfected.  
 
6.3.2 Transdifferentiation protocol 
 
Transdifferentiation was performed according to the protocol published in the original 
paper91.  
2 or 7 days after 4-OHT treatment MEFs were seeded in MEFs medium on Matrigel 
Basement Membrane Growth Factor Reduced (BD Biosciences, catalog number 354230) 
coated dishes. Matrigel was thawed on ice and diluted 1:50 in DMEM/F-12 (1:1) (F-12 
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Nut Mix (1X) + GlutaMAX; Gibco, catalog number 31765-027). Polymerization was 
performed either at 37 °C for 30 minutes or overnight at 4 °C. In the second case, before 
plating the cells, dishes and/or multichambers were left at room temperature for at least 1 
h. 
The excess of matrigel was removed and the desired number of MEFs was seeded. The 
following day MEFs were transduced with the four vectors (0.5 µl of each vector for each 
50000 cells). 
Doxycycline (1:1000, mother stock 2 µg/µl) was administered the day after transduction 
and then every other day until the end of the analysis. 
The 5th day after plating, MEFs medium was replaced with Neurobasal medium (plus 
doxycycline). 
Neurobasal medium composition: 
Neurobasal minus phenol red (ThermoFisher Scientific, catalog number 12348017) 
1% Penicillin/Streptomycin (Life Technologies, catalog number 15140-122) 
1% L-Glutamine (Life Technologies, catalog number 25030-024) 
1% N-2 Supplement 100X (ThermoFisher Scientific, catalog number 17502048) 
2% B-27 Supplement, serum free 50X (ThermoFisher Scientific, catalog number 
17504044) 
 
6.4 Transdifferentiation outcome evaluation 
6.4.1 ScanR images acquisition 
6.4.1.1 Immunofluorescence  	
For ScanR experiments MEFs were seeded in different concentrations in Nunc Lab-Tek 
permanox chamber slides (2 wells, Sigma Aldrich, catalog number C6682). 
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One day after doxycycline and 13 days after plating, cells were fixed with 4% 
paraformaldehyde, 20 minutes on ice. 
Afterwards cells were washed 3 times with PBS and permeabilized with PBS, 10% FBS, 
0.1% Triton X-100 30 minutes at room temperature. 
Fixed cells were incubated with primary antibodies, diluted in PBS, 10% FBS, at 4°C 
overnight in agitation. 
The day after 3 washes with PBS were executed followed by 1 h incubation with the 
secondary antibodies (diluted in PBS, 10% FBS) at room temperature, in agitation. DAPI 
was added to the secondary antibodies mix. 
Subsequently slides were mounted with Vectamount AQ Mounting Medium (Vector 
Laboratories, catalog number H-5501) and imaged the day after. 
The list of antibodies is reported in Table 3 and Table 4. 
 
 
Table 3: Primary antibodies used for immunofluorescence 	
 
 
Table 4: Secondary antibodies and DAPI used for immunofluorescence 
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6.4.1.2 Images acquisition 	
A grid of 100 images per embryo in duplicate was acquired with the BX61 upright 
microscope equipped with a motorized stage from Olympus. 
The software name was ScanR (Olympus) and the objective utilized was the 20x with a 
0.75 Numerical Aperture. 
 
6.4.1.3 Images analysis 
 
One day after doxycycline the number of cells per image was manually evaluated as 
number of DAPI. Each concentration was analysed and, at the end, only conditions with 
the same cell number at this time point were compared. At 13 days after plating, cells 
positive for Class III β-tubulin (Tuj1) were classified as iNs and manually quantified. The 
efficiency of transdifferentiation was calculated as the percentage of Tuj1+ cells among the 
number of DAPI at 3 days after plating.  
To calculate neurite length an Imagej plugin called NeuriteTracer was used129. This plugin 
traces neurites in images stained with a neuronal marker, present also in dendrites and 
axons, such as Tuj1. Then it estimates the area covered by them subtracting from this value 
the area of nuclei that intersect them. Because this calculation depends on the number of 
neurons the plugin-retrieved value was divided for the number of Tuj1+ cells. 
For the experiments executed with ScanR unpaired t test was performed as statistical 
analysis.  
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6.4.2 Cytofluorimetric analysis 
6.4.2.1 Samples preparation 
 
Cells were detached with Accutase (Sigma-Aldrich, catalog number A6964) and counted 
with the Countess Automated Cell Counter (ThermoFisher Scientific) in duplicate, 5, 7, 9, 
13 and 21 days after they were plated for transdifferentiation. After their centrifugation, in 
a tabletop refrigerated centrifuge at 4 °C for 10 minutes, at the minimum speed, they were 
resuspended in up to 106 cells per 100 µl of cold PBS-FACS (Fluorescence-Activated Cell 
Sorting) (PBS 0.5% FBS, 2nM EDTA). 10µl of Polysialic Acid Neural Cell Adhesion 
Molecule (PSA-NCAM) antibody (Miltenyi, catalog number 130-093-273) were added 
and the suspension was mixed and kept in the dark on ice for 10 minutes. Afterwards cells 
were washed with 1 ml of cold PBS-FACS and centrifuged in a tabletop refrigerated 
centrifuge at 4 °C for 10 minutes at the minimum speed. Pellet was resuspended in 300µl 
of cold PBS-FACS and 3 minutes before each tube was acquired, 5-10 µl of Propidium 
Iodide (PI) (Sigma Aldrich, catalog number P4170-1G. stock 50µg/ml in dH20) were added 
and mixed. Tubes were kept in the dark on ice. 
 
6.4.2.2 Samples acquisition and analysis 
 
Samples were acquired at BD FacsCalibur with the BD CellQuest Pro Software and 
analysed with the Flowjo software. 
As statistical analysis unpaired t test was executed. 			
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6.5 High-throughput experiments 
6.5.1 FACS sorting 
 
FACS sorting was executed on 4-OHT treated MEFs (5 days) left in culture 7 days before 
transdifferentiation. 107 MEFs were plated on matrigel coated dishes both for the RNA-seq 
and the ChIP-seq on iNs at 13 days. Cells were sorted for PSA-NCAM positivity after a 
short detachment with Accutase. The protocol of staining was the same as the one used for 
the cytofluorimetric analysis (paragraph 6.4.2.1). 
Cells were sorted at MoFlo Astrios (Beckman Coulter) with the Software Summit v6.2. 
 
6.5.2 RNA-seq 
6.5.2.1 RNA extraction 
 
RNA was extracted immediately after sorting with RNeasy micro kit (QIAGEN 74004). 
This kit was chosen because it is exploitable for low cell amounts and it is optimum for the 
extraction of messenger RNA (mRNA) (due to the prevalent selection of RNA molecules 
longer than 200 nucleotides).  
Briefly, cells were resuspended in a denaturing buffer containing guanidine-isothiocyanate 
(RLT buffer) plus β-mercaptoethanol, to inactivate the RNases, and then passed 5 times 
through a blunt 20-gauge needle. Afterwards ethanol was added to the solution to favour 
the exclusive binding of RNA to the RNeasy MinElute spin column. DNA contamination 
was eliminated adding the DNase I directly to the column and incubating for 15 minutes. 
After some washes, RNA was eluted in 14 µl of RNase free water and quantified at 
Nanodrop Spectrophotometer. RNA quality was evaluated at Agilent 2100 Bioanalyzer 
with the Agilent RNA 6000 Nano kit (catalog number 5067-1511). 
		 60	
6.5.2.2 Libraries preparation 
 
Libraries were prepared following the TruSeq Stranded Total RNA Sample Preparation 
manufacturer’s guidelines (Illumina) starting from 100 ng of RNA per sample.  
Briefly, the steps that this protocol entailed were the following. First, through the usage of 
biotinylated oligos that recognized ribosomal RNA (rRNA) and of ad hoc beads (Ribo-
Zero rRNA magnetic removal beads), mRNA was purified. 
Afterwards mRNA was fragmented using divalent cations at 94 °C and retrotranscribed 
with random primers. The second cDNA strand was synthesised using the DNA 
polymerase I and the RNAse H. Beads (AMPure XP beads) were used to purify the ds 
cDNA. Overhangs resulting from fragmentation were converted into blunt ends using an 
End Repair Mix. Afterwards a single adenine was added to the 3’ ends of cDNA and 
specific adapters were ligated to it, through their 3’ overhang thymine. Finally a step of 
PCR amplification was performed, using primers specific for the adapters, to enrich only 
for ligated cDNA. 
The quality of the libraries was tested at Agilent 2100 Bioanalyzer with the High 
Sensitivity DNA kit (catalog number 5067-4626). 
Libraries were sequenced with the Illumina HiSeq machine at a read length of 100 bp, 
paired end, and a coverage of 120 millions of reads. 
 
6.5.2.3 RNA-seq bioinformatic analysis 
6.5.2.3.1 Alignment and quantification 	
RNA-seq reads were aligned with TopHat v2.0.10130, first to mm10 Refseq transcriptome, 
and genes without a perfect alignment were realigned to genome (i.e., --read-edit-dist 2). 
Quantification was performed on the Refseq transcriptome using Cuffquant v2.2.1, with 
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multi-read correction (-u)130. This pipeline was selected because it was one of the highest-
performing quantification methods in our recent benchmark131. 
 
6.5.2.3.2 Differential expression analysis 	
For the differential expression analysis, we first excluded genes which had an average read 
count across samples below 50. We used edgeR v.3.12.1 (which outperformed other 
methods according to our benchmark) on the TMM-normalized estimated fragment counts. 
Specifically, edgeR fitted a generalized linear model that takes sex into account 
(~sex+genotype) on the normalized log-transformed count of each gene, and then tested, 
using a likelihood ratio test, whether the model including the genotype variable 
significantly improved the fit over the model not including it. We considered differentially 
expressed with high confidence genes with a FDR below 0.01 and an absolute 
log2(foldchange) greater than log2(1.5). 
 
6.5.2.3.3 Alternative splicing/Differential exon usage 	
Alternative splicing is notoriously difficult to test statistically, and the most robust method 
for doing so is based on differential exon usage132. Differential exon usage is not exactly 
the same as alternative splicing: strictly speaking, it detects changes in the coverage of an 
exon that are associated with the independent variable, and that are discordant with 
variations in the other exons of the same gene. This means that alternative TSS or 
transcription end site results in differential exon usage, although they are generally not 
considered alternative splicing. However, all alternative splicing events result in 
differential exon usage. 
Differential exon usage is based on the number of fragments overlapping each exon, we 
which obtained using featureCounts v.1.4.4133 with the -O -f options on the TopHat 
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alignments. We then tested for significant differences using DEXseq v.1.16.7 as described 
in the manual. 
 
6.5.2.3.4 Enrichment analyses 	
Gene Ontology enrichment analyses were performed using the goseq v.1.22.0 R package in 
order to correct for RNA-seq transcript length bias134, using Fisher's test and excluding 
genes without annotation. Categories with at least 10 genes and maximum 1500 genes 
were considered. When the number of enriched categories was large, we focused on the 
most specific categories by removing any category with enriched children categories. 
(based on the graphs of the GO.db R package). Quilts were generated using the treemap R 
package. 
 
6.5.2.5 RNA-seq validation 
 
The RNA was retrotranscribed through the SuperScript VILO cDNA Synthesis Kit 
(Invitrogen, catalog number 11754-050). 
Real Time Quantitative PCR (RT-qPCR) was performed on 7500 Fast Real-Time PCR 
system (Applied Biosystems) using Sybr green (Applied Biosystem) as detecting reagent. 
Each sample was analyzed in triplicate and normalized to Gapdh. Relative mRNA quantity 
was calculated by the comparative cycle threshold (Ct) method using the formula 2-ΔCt. 
cDNA was amplified (in triplicate) in a reaction volume of 20 µl containing 9µl of cDNA 
in ddH2O and 11µl of 10 µM primers and Sybr green. The protocols envisaged the 
following steps: 20 seconds at 95°C, followed by 40 cycles of 3 seconds at 95°C, 30 
seconds at 60°C and 15 seconds at 95°C. Afterwards a dissociation stage was present: 1 
minute at 60°C, 15 seconds at 95°C and 15 seconds at 60°C. Each primers pair was 
checked for its efficiency of amplification. If y= - ax + q was the trendline equation, 
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obtained by amplification of quadratic increasing quantity of cDNA, the efficiency was 
calculated as (10^(-1/a)-1)*100. Only pairs of primers with efficiency between 95 and 110 
were used for further analysis.  
Primers are listed in Table 5. 
 
Table 5: Primers used in qRT-PCR 
 
6.5.3 Chromatin immunoprecipitation coupled to deep-sequencing (ChIP-seq) 
6.5.3.1 ChIP-seq libraries preparation 
 
107 MEFs were plated for the ChIP-seq for MENIN and H3K4me3 at 13 days, while, in 
the case of the ChIP-seq for H3K4me3 at 5 days, 5 millions of MEFs were seeded, in both 
cases in 15-cm dishes.  
At the desired time point, medium was removed and cells were fixed with 15 ml of PBS 
1% formaldehyde for 10 minutes. By this step proteins and DNA were cross-linked. To 
stop fixation 1 ml of glycine 2 M (final concentration 0.125 M) was added for 5 minutes. 
Plates were washed twice with PBS and then cells were scraped and collected in SDS 
Buffer. At this point cells could be stored at -80 °C until they were processed. Thawing 
occurred in water bath at room temperature. Cells were centrifuged in a tabletop centrifuge 
for 10 minutes at 400 g and then resuspended in 3 ml of ice-cold IP buffer.  
Sonication was performed on ice through the Digital Sonifier 450 (Branson) with the 102C 
CONVERTER (Branson). 
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ChIP-seq for Menin (5 days) 3 cycles 30’’ on/30’’ off at 30% amplitude, length 700 bp. 
ChIP-seq for H3K4me3 (5 days) 7 cycles 30’’ on/30’’ off at 30% amplitude, length 200 
bp. 
ChIP-seq for H3K4me3 (sorted cells, 13 days) 4 cycles 30’’ on/30’’ off at 30% amplitude, 
length 200 bp. 
Part of the sonicated material was decrosslinked with the decrosslinking buffer for 1h at 65 
°C, purified with the QiaQuick PCR Purification kit (Qiagen, catalog number 28104), 
according to manufacturer’s guidelines, and run on a TAE 1% agarose gel to evaluate the 
DNA fragments length. 
Sonicated chromatin was centrifuged at full speed for 30 minutes and the supernatant was 
transferred to a new tube. The quantity of chromatin was estimated using Bradford assay, 
using BSA (NEB) to derive a standard curve. 2 µl of sonicated chromatin were diluted in 
800 µl of water plus 200 µl of Biorad Protein Assay and the absorbance at 595 nm was 
measured by a spectrophotometer. 
Immunoprecipitation was performed in 1 ml of IP buffer on a rotating wheel at 4°C 
overnight using the antibodies and the conditions listed in the Table 6.  
 
 
Table 6: Antibodies used for ChIP-seq 
 
10 µl of sonicated chromatin was kept as input control (1% input). 
The following day 30 µl of protein G dynabeads (ThermoFisher Scientific, catalog number 
10003D) (pre-equilibrated with IP Buffer) were added and the mix was incubated for 4 h 
on a rotating wheel at 4°C. Afterwards beads were washed 3 times with 1 ml of 150 mM 
Wash Buffer and once with 1 ml of 500 mM Wash Buffer with the use of a Dynamag 
magnet (ThermoFisher Scientific, catalog number 12321D). 
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Afterwards beads (and the 1% input) were resuspended in 120µl of Decrosslinking Buffer 
and put in agitation (at full speed) at 65 °C overnight. 
Finally DNA was purified with the QiaQuick PCR Purification kit (Qiagen, catalog 
number 28104), eluted in 40µl of ddH2O and quantified with Qubit dsDNA HS Assay Kit 
(ThermoFisher Scientific, catalog number Q32851) at the Qubit 2.0, following 
manufacturer’s instructions. 
The purified DNA was given to the sequencing facility of the IFOM/IEO Campus that 
prepared the libraries as in paragraph 6.5.2.2. The starting amount of DNA was 5 ng for 
MENIN and H3K4me3. Libraries were sequenced on a HiSeq 2000 instrument (Illumina) 
following manufacturer's protocol. Sequencing was performed in single end, 50 bp, with a 
coverage of 30 millions of reads for inputs, H3K4me1 and menin ChIP-seq. 
Buffers: 
SDS Buffer: 
100mM NaCl  
50mM Tris-HCl pH 8.1  
5mM EDTA pH 8  
0.5% SDS  
 
Triton Dilution Buffer: 
100mM NaCl 
100mM Tris-HCl pH 8.6 
5mM EDTA pH 8  
5% Triton X-100  
 
IP Buffer: 
2 volumes SDS Buffer: 1 volume Triton Dilution Buffer 
 
150mM Wash Buffer: 
150mM NaCl  
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20mM Tris-HCl pH 8  
2mM EDTA pH 8  
0.1% SDS  
1% Triton X-100  
 
500mM Wash Buffer: 
500mM NaCl  
20mM Tris-HCl pH 8  
2mM EDTA pH 8  
0.1% SDS  
1% Triton X-100  
 
Decrosslinking Buffer  
1% SDS 
0.1M NaHCO3 
 
6.5.3.2 ChIP-seq bioinformatic analysis 
6.5.3.2.1 Alignment and peak calling 
 
ChIP-seq reads were trimmed for potential adapter contamination using scythe 0.981 (min 
4 nucleotides) before being aligned to the mm10 genome using bowtie 1.0135 with -v 2 -m 
1, and peaks were called using MACS 2.0.9136 with default settings. MACS uses sliding 
windows to look for significant enrichment over the input, and relies on a shifting model 
(detecting the average fragment size from the gap between sub-peaks originating from 
each end of the fragments) to refine the boundaries of the modification or binding event. 
Although we relied mostly on quantitative analyses (below) to compare across replicates 
and conditions, when comparing peaks directly we considered peaks as overlapping if they 
shared at least one nucleotide. 
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6.5.3.2.2 Identification of target genes 	
Proximally bound genes were defined as having a peak within a -2.5kb/+1kb window 
around any of their RefSeq TSS. To identify the putative targets of intergenic sites bound 
by MENIN but in contact with a TSS only through chromatin conformation, we relied on 
Hi-C data from the most similar cell type available, namely neural progenitors. We 
downloaded already processed, statistically significant interactions from the Gene 
Expression Omnibus entry GSE68582, extracted a bed file containing each region 
interacting with a RefSeq TSS, and intersected it (using intersectBed) with our regions of 
interest to find distal targets. 
 
6.5.3.2.3 Quantitative analysis of ChIP-seq data 	
Peak calling is very sensitive to coverage and technical variation, and quantitative analysis 
of read distribution yields considerably more robust findings. To find differences across 
conditions, we therefore worked on the distribution of reads falling within relevant 
genomic windows. For each protein/mark, the windows were defined by merging the 
enriched regions across samples (i.e., with BedTools: cat *.bed | sortBed -i - | mergeBed -i 
-). In this way, all regions enriched in at least one sample were considered for statistical 
testing, without duplicate genomic regions. The read counts were then compared across 
conditions using edgeR v.3.12.1137,  using the total number of mapped reads as library size 
and the TMM method for normalization. Differentially enriched regions were identified 
using the classical dispersion model of edgeR (based on a negative binomial model) and 
the exact test.  
For the MENIN ChIP-seq, given the low quality of the peak calling (very low and variable 
number of peaks across samples, probably owing to a low and highly variable coverage), 
we performed a peak-call-agnostic differential enrichment analysis using diffReps138, 
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which uses sliding windows to directly identify regions of significant difference between 
sets of enrichment profiles. 
 
6.5.3.2.4 Data representation (RNA-seq and ChIP-seq) 	
Principal component analyses were performed on the normalized, log-transformed FPKM 
(for RNA-seq) or read counts (for ChIP-seq). Unless specified otherwise, all heatmaps 
show row z-scores of log-transformed normalized counts. Heatmaps were produced using 
the pheatmap R package. +1 was added before log-transform to avoid errors on null values. 
 
6.5.3.2.5 External data (RNA-seq and ChIP-seq) 
For external datasets, we used the authors' original peak calls (ChIP-seq) or quantification 
(RNA-seq) that are available from the respective GEO entries.  
 
6.6 Embryonic Stem cells (ESCs) MLL2-EGFP 
6.6.1 ESCs culture 	
ESCs were cultured on 0.2% gelatin coated dishes. Medium, supplemented with G418 
(200 µg/ml), was changed every day. Cells were passaged by Accutase. 
As control for in vitro differentiation studies the ESCs E14TG2alpha have been used and 
cultured as ESCs MLL2-EGFP. 
ESCs Medium composition: 
DMEM without L-Glutamine (Lonza, catalog number BE12-614F) 
15% FBS (Euroclone, catalog number ECS0196D) 
0.2% LIF (produced by the Transgenic Unit of the IFOM-IEO campus) 
1% L-Glutamine 200mM (Life Technologies, catalog number 25030-024) 
1% Non-essential aminoacids (Lonza, catalog number BE13-114E) 
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0.2% β-mercaptoethanol 50 mM (Life Technologies, catalog number 31350-010) 
 
plus or minus 2 inhibitors (2i): 
MEKi PD-0325901 1 µM (mother stock 10mM Sigma-Aldrich, catalog number PZ0162) 
GDK3i CT-99021 3 µM (mother stock 10mM Sigma-Aldrich, catalog number SML1046) 
Mll2 exon 2 copy number was tested through Taqman as in the paragraph 6.2.3. 
Immunofluorescence was performed as in the paragraph 6.4.1.1. 
 
6.6.2 ESCs differentiation toward fibroblasts 
6.6.2.1 In vitro differentiation 	
Differentiation was performed adapting the protocol of the paper of Xu and coworkers139. 
Briefly 3.7 106 ESCs were plated in 10cm nonadherent cell culture dishes in: 
DMEM without L-Glutamine (Lonza, catalog number BE12-614F) 
1 mM L-Glutamine (Life Technologies, catalog number 25030-024) 
0.1 mM β- mercaptoethanol (Life Technologies, catalog number 31350-010) 
10% FBS (HyClone, catalog number SH30088.03) 
1% Nonessential aminoacids (Lonza, catalog number BE13-114E) 
After 4 days the clear appearance of embryoid bodies (EB) was observed. EBs were 
replated on 0.2% (w/v) gelatin coated dishes for 9 days. The EBs outgrowth cells were 
dissociated in 2mg/ml collagenase type II for 30 minutes at 37°C and replated in MEFs 
medium (paragraph 6.2.1). Afterwards cells were passaged in trypsin. 
Immunofluorescence was performed as in paragraph 6.4.1.1. 
 
6.6.2.2 MEFs derivation from chimeras 
 
ESCs injection into the blastocysts was performed by the Transgenic Unit of the IFOM-
IEO campus. 
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Briefly, blastocysts were harvested 3.5 days post coitum from 3 weeks C57Bl/6 female 
mice treated with Pregnant Mare Serum Gonadotropin (PMSG) (5 UI/female) and human 
Chorionic Gonadotropin (hCG) (5 UI/female), subsequently bred with C57Bl/6 males. 
Pseudo-pregnancy was induced through the breeding of C57Bl/6 females with 
vasectomized mice. Once plugged they were anesthetized (Avertin 1.25%, analgesic 
Rimadyl (5mg/kg) or Tramador (20µg/g)) and the chirurgic embryo transfer was 
performed (20-28 blastocysts per female). 
Embryos were harvested at E.13.5 and MEFs preparation was executed as in paragraph 
6.2.1.  
MEFs selection was performed supplementing MEFs medium with G418 (100 µg/ml or 
200 µg/ml). Mll2 exon 2 copy number was tested through Taqman as in the paragraph 
6.2.3. 
6.6.2.3 Fibroblasts derivation from teratomas 
 
106 ESCs per side were injected subcutaneously in the flank of NOD SCID IL2Rγ-/- mice.  
Teratomas were harvested and digested in collagenase I (750U/ml) for 1h. Then they were 
filtered through 0.1µm pore nitrocellulose filter and centrifuged at 500g for 3 minutes. Red 
blood cells were lysed 1 minute in ACK lysing buffer (ThermoFisher Scientific, catalog 
number A1049201). MEFs medium was added to stop the lysis and cells were centrifuged 
at 500g for 3 minutes. 
Pellet was dissociated in trypsin, subsequently inactivated by the medium addition. Finally 
cells were centrifuged at 500g for 3 minutes and plated in MEFs medium at 37°C, 5%CO2 
3%O2.  
Parts of the teratoma were not dissociated, but washed in PBS and fixed overnight in 4% 
formalin solution. The following day they were processed by an automatized tissue 
processor and included in paraffin blocks.  4 µm thick sections were cut with a Leica 
microtome and stained with haematoxilin and eosin to assess the trilineage specification.  
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The immunohistochemistry staining was performed by the IEO hospital Molecular 
Pathology Unit. 
Sections were washed in Bioclear (Bio Optica), hydrated through descending graded 
alcohol series and then wash in ddH2O. Subsequently the antigen retrieval (in EDTA 1mM, 
Tween-20 0.05% pH 8) at 95°C was performed and endogenous peroxidase was quenched 
with 3% H2O2 for 5 minutes. 
Sections were then incubated in blocking buffer (2% BSA in TBST) for 20 minutes and, 
subsequently with the rabbit anti-GFP antibody (Santa Cruz, sc-8334), diluted in blocking 
buffer, for 1h. After 3 washes, the secondary antibody (anti-rabbit Dako EnVision+ 
System-HRP Labeled Polymer) was added for 30 minutes. 
Afterwards they were incubated with Dako Liquid DAB + Substrate Chromogen System, 
counterstained with hematoxylin (10 seconds), dehydrated through ascending graded 
alcohol series and mounted with Eukitt (Bio Optica). Signals were revealed using Dako 
EnVision+ Kit. 				
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7. RESULTS 
7.1 Establishment of the experimental system 
 
The mouse models used in this study are conditional knock-out for Mll1128, Mll256 or both, 
since the straight knock-out for these genes is embryonic lethal55,56. The strategy envisaged 
in Mll1, Mll2 and Mll1/Mll2 conditional knock-out is the same: mice harbour a tamoxifen 
inducible Cre (CreERT2) in the ROSA26 locus, and the exon 2 of the gene encoding the 
specific methylase is flanked by LoxP sites (Figure 10a). Upon 4-hydroxytamoxifene (4-
OHT) administration the exon 2 is deleted causing a frameshift mutation. In particular 
Mll1 and Mll2 mRNA translation is immediately blocked, due to a new stop codon being 
formed at the beginning of exon 3 (Figure 10b). These mouse models bear also the YFP 
gene in the ROSA26 locus, downstream to a stop cassette flanked by LoxP sites. Initially 
we used the YFP positivity as an indirect indication of the entity of CRE recombination, 
but we later replaced this assay by ad hoc TaqMan assays. 
 
 
 
Figure 10: Schematic of the mouse models used in this study 
a. Transgenic alleles of the mouse models. All the transgenic mice used in this study harbour the 
CreERT2 and YFP genes in the Rosa26 locus. The latter is downstream to a stop cassette between 
LoxP sites (blue triangles). Moreover the Mll gene, depending on the considered conditional knock-
out analysed, has the exon 2 (ex2) flanked by LoxP sites. b. Deletions occur upon 4-OHT 
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administration. Once 4-OHT is added to the culture medium, CRE is activated leading to the 
deletion of both the stop cassette and the Mll exon 2. This causes a frameshift mutation in the Mll 
gene. 
 
To obtain the complete deletion of exon 2, reducing to the minimum the toxicity of 4-OHT 
itself and of Cre activity, I conducted several experiments to define the optimal 4-OHT 
concentration and length of the treatment, that resulted in 5 days 1000ng/ml of 4-OHT 
(Figure 11a). As controls we used MEFs Mll1+/+Mll2+/+CreERT2+YFP+ 4-OHT-treated, to 
discriminate between the effects due to the absence of the specific MLL protein and the 
toxicity and aspecific effects of 4-OHT administration and Cre activity. Before MEFs were 
replated on matrigel for transduction with BAM factors they were left to recover in the 
medium without 4-OHT for either 2 or 7 days (Figure 11a). By leaving MEFs 7 additional 
days in culture before plating them, any residual MLL1 and/or MLL2 protein should be 
degraded and/or diluted. Hence, also the H3K4me3 mark at MLL1 and MLL2 targets 
should cease to be maintained, given our current knowledge of the dynamics of this mark. 
The degradation of MLL1 is timely regulated by the cell cycle. Indeed, MLL1 remains 
associated with DNA during replication, preserving the configuration of the epigenome79,80 
and it is degraded during late S and M phases78. It is therefore reasonable to expect that 5 
days of 4-OHT treatment plus 2 days of normal medium should be already sufficient for 
the degradation of the residual MLL1 and for the removal of the MLL1-H3K4me3-
deposited mark. The ESCs used to derive the Mll2 conditional knock-out strain used in this 
study show the disappearance of MLL2 with as little as 2 days of 4-OHT treatment64. 
Hence, as for Mll1, 5 days of 4-OHT plus 2 days in normal medium should be sufficient to 
eliminate the MLL2 translated prior to the induction of Cre recombinase activity. 
Moreover we hypothesised that waiting an additional week before plating the MEFs for 
transdifferentiation would let us be more confident about MLL1 and MLL2 degradation. 
Even though the compensation by the homolog protein (which is, however, not present in 
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the double knock-out MEFs) or by other TrxG members can not be excluded by this 
strategy, any observed deficiency in transdifferentiation can be ascribed to a role of the 
specific MLL protein during cell conversion. 
In all the experiments cells were collected and tested for the efficiency of exon 2 deletion 
on the day when they were plated for transdifferentiation. Specifically the deletion was 
confirmed at the genomic level, with TaqMan assays (Figure 11c), and in the case of Mll2 
also at the protein level (Figure 11d).  
To understand whether the absence of the two MLLs plays a role during 
transdifferentiation I performed two types of experiments: immunofluorescence with 
images acquired at a modular microscope-based imaging platform (ScanR experiments) 
and cytofluorimetric analysis (FACS experiments) (Figure 11b). The aim of ScanR 
experiments was the semi-quantitative assessment of transdifferentiation efficiency and 
cell mortality, but more importantly of iNs morphology/maturation, not appreciable with 
other techniques. FACS kinetics was instead performed to measure the percentage of 
transdifferentiating MEFs and the mortality rate during the entire process. 
For what concerns ScanR analysis, the experiments were carried out as follows. Different 
concentrations of cells were plated for experimental (flox/flox 4-OHT treated, named -/- in 
the rest of the thesis) and control conditions (+/+ 4-OHT treated or fl/+ 4-OHT treated, in 
the case of Mll1, named respectively +/+ and +/- in the rest of the thesis). The number of 
DAPI cells was counted at day 3, one day after the first doxycycline administration (i.e., 
the plausible onset of transdifferentiation) and at the end only the conditions that at this 
time point were in the same number were compared to calculate transdifferentiation 
efficiency (Figure 11b). In fact, since any of the two epigenetic modulators is important for 
the regulation of cell viability/cycle61,84,85,140 despite plating the same number of cells there 
could be a different number of cells in the control and the experimental condition at the 
moment of induction of the TFs. This could influence the final number of iNs. Since it has 
been demonstrated that in the day after the first doxycycline administration the majority of 
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the cells are postmitotic91, it was considered as the starting point. By using this strategy 
any difference in transdifferentiation efficiency is imputable to an effect of MLL on the 
process per se or on the cell viability, both testable by our analysis. 
In the case of FACS experiments only Mll+/+ was included as control, and Polysialylated-
neural cell adhesion molecule (PSA-NCAM) was used as a neuronal surrogate marker141, 
whereas mortality was evaluated with Propidium Iodide (PI) staining. Moreover at the 
same time points of FACS analysis, cells were also counted to better assess the cell death 
rate. 
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Figure 11: Experimental set-up 
a. After 4-OHT treatment MEFs were plated for transduction with BAM factors either after 2 or 7 
days in normal media. b. For ScanR experiments (time points in green boxes) experimental and 
control MEFs were plated in multichambers in different concentrations and imaged 3 and 13 days 
after plating. Only conditions that at 3 days after plating were in the same number were compared 
at the end (red boxes). For FACS experiments (time points in blue boxes) cells were analysed 5, 7, 
9, 13 and 21 days after plating. c. Representative TaqMan results for exon 2 copy number of both 
Mll1 and Mll2. Means +/- Standard Error of the Mean (SEM) are reported. d. Western blot for 
MLL2 (bands at 284 kDa and 225 kDa) with VINCULIN as housekeeping (116 kDa) in ESCs and 
4 Mll1+/+Mll2+/+, 3 Mll2-/- and 1 Mll1-/-Mll2-/- MEFs treated 5 days with 4-OHT and left 7 days in 
MEFs medium without 4-OHT. 
 
7.2 MLL1 is dispensable during transdifferentiation 
 
Two ScanR experiments were performed plating MEFs 2 days after the last 4--OHT 
administration and using Mll1+/- MEFs as control.  
In the first experiment we observed a higher mortality of Mll1-/- than controls (Figures 12a 
and 12c on the left) and, consequently, both a lower percentage of Tuj1+ cells at day 13 
(Figure 12d) and an overall lower transdifferentiation efficiency in the experimental 
condition (Figure 12f on the left). On the contrary, in the second experiment, the mortality 
rate of Mll1+/- was higher (Figures 12b and 12c on the right), at 13 days there was no 
difference in the percentage of Tuj1+ cells between the experimental condition and the 
control (Figure 12e) and the transdifferentiation efficiency was higher in Mll1-/- (Figure 12f 
on the right).  
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Figure 12: Transdifferentiation in the absence of MLL1: ScanR experiments 
a. and b. Cell mortality in the absence of Mll1 in experiments 1 and 2 respectively (exp1 and exp2). 
The number of DAPI in 100 images per genotype is reported. On the left the two conditions in the 
same number, one day after the first doxycycline administration (starting point, +3) and on the 
right the number of DAPI in the chosen concentration at 13 days (end of the protocol, +13). Means 
+/- SEM are reported. c. Cell mortality reported as the ratio between the sum of DAPI calculated 1 
day after doxycycline administration at the chosen concentration (DAPI start) and the sum of DAPI 
of the corresponding chamber at 13 days (DAPI end) in the two experiments (exp1 and exp2). 
Means +/- SEM are reported.  d. and e. Percentage of Tuj1+ cells among total DAPI in 100 images 
acquired for the chosen concentration at 13 days, for the experiment 1 and the experiment 2 
respectively (exp1 and exp2). ). Means +/- SEM are reported. f. Efficiency of transdifferentiation in 
the two experiments (exp1 and exp2). The number of Tuj1+ cells for the chosen concentration at 13 
days was calculated and related to the number of DAPI quantified 1 day after doxycycline 
administration. Means +/- SEM are reported. *** p<0.0001; ** p<0.001; *p<0.01; ns not 
significant p>0.01. 
 
These results suggest that the differences observed in transdifferentiation efficiency are the 
consequence of a difference in mortality rate among experiments. However, having only 
one copy of the Mll1 gene could be sufficient for altering the cell mortality rate and/or the 
transdifferentiation efficiency. Afterwards, FACS experiments were performed using 
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Mll1+/+ as a control and leaving MEFs in culture one additional week before plating them 
for BAM factors transduction. By means of this strategy we could exclude both a role of 
haploinsufficiency and that the phenotype observed was due to some residual MLL1 
present in the knock-out MEFs at the onset of transdifferentiation. Unfortunately there are 
no effective commercial anti-MLL1 antibodies to test its presence. 
The mortality rate was slightly higher during all analysed time points in the experimental 
condition with respect to the control (Figures 13a and 13b). The percentage of PSA-
NCAM+ cells, instead, was similar in Mll1+/+ and Mll1-/- throughout the experiment and as 
long as 21 days after plating (Figure 13c).  
However, when transdifferentiation efficiency was calculated as the percentage of PSA-
NCAM+ cells generated at 13 days with respect to the number of MEFs plated for BAM 
transduction it resulted lower in the Mll1-/- condition compared to the control (Figure 13d).  
 
 
 
 
a	 b	
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Figure 13: Transdifferentiation in the absence of MLL1: FACS experiments 
a. The total number of cells was calculated 5, 7, 9, 13 and 21 days after plating with the Countess 
Automated Cell Counter. The percentage of dead cells was calculated over the initial number of 
plated MEFs. Means +/- SEM are reported. Mll1-/- n=3; Mll1+/+ n=3 at all time points, but day 21: 
n=2. b. Mortality rate as percentage of PI+ cells 5, 7, 9, 13 and 21 days after plating, assayed with 
FACS analysis. Means +/- SEM are reported.  Mll1-/- n=3 at all time points, but day 21 in which 
n=2; Mll1+/+ n=3 at all time points, but day 21 in which n=1. c. Percentage of PSA-NCAM+ cells 5, 
7, 9, 13 and 21 days after plating, assayed with FACS analysis. Means +/- SEM are reported.  Mll1-
/- n=3 at all time points, but day 21 in which n=2; Mll1+/+ n=3 at all time points, but day 21 in which 
n=1. d. Efficiency of transdifferentiation calculated as the percentage of PSA-NCAM+ iNs cells at 
13 days with respect to the number of plated cells. Means +/- SEM are reported. Mll1-/- n=3; Mll1+/+ 
n=9. *** p<0.0001; ** p<0.001; *p<0.01; ns not significant p>0.01. 
 
Since the percentage of PSA-NCAM+ cells for the two genotypes remained the same 
throughout the experiment, the observed lower efficiency should be attributable to the 
higher cell death rate in Mll1-/- condition. 
Hence, also with the inclusion of the Mll1+/+ cells as control, the lower transdifferentiation 
efficiency observed in Mll1-/- cells corresponds to a higher cell death.  
Finally, in 2 out of 2 experiments, neurites of Mll1-/- iNs extended as in the Mll1+/- control 
(Figures 14a and 14c), further suggesting that MLL1 has no appreciable role during 
transdifferentiation. Although an ad hoc experiment would be required to prove it 
numerically, it is highly unlikely that this was due to haploinsufficiency because neurite 
length in the Mll1+/- condition was visually comparable to Mll1+/+ one. Moreover both 
Mll1-/- and Mll1+/- iNs at 13 days were positive for the Microtubule associated protein 2b 
(MAP2b) (Figure 14b), a more mature neuronal marker, underlining that the absence of 
Mll1 does not impair transdifferentiation.  
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Figure 14: The absence of Mll1 does not impair iNs morphology 
a. Representative images of Mll1+/- (upper panels) and -/- (lower panels) iNs (DAPI is in blue and 
Tuj1 in red) at 13 days. b. Representative images of Mll1+/- (upper panels) and -/- (lower panels) iNs 
(DAPI is in blue, Tuj1 in red, MAP2b in green) at 13 days. c. Average neurite length per neuron 
calculated with Neuritetracer. Means +/- SEM are reported. ns: not significant (p>0.01). 
 
7.3 MLL2 is necessary during transdifferentiation 	
The absence of MLL2 could impair the number of iNs generated because MLL2 has an 
active role during transdifferentiation, but also because Mll2 deletion could lead to a higher 
cell mortality. However the cell viability of Mll2-/- transdifferentiating MEFs did not result 
affected, as demonstrated by ScanR experiments (3 out of 3 experiments) (Figures 15a and 
15d on the left) and by PI staining (Figure 16d). 
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Figure 15: Transdifferentiation in the absence of MLL2: ScanR experiments 
a. Cell mortality in the absence of Mll2 in one representative experiment. The number of DAPI in 
100 images per genotype is reported. Means +/- SEM are reported. On the left the two conditions 
in the same number one day after the first doxycycline administration (starting point, +3) and on 
the right the number of DAPI in the chosen concentration at 13 days (end of the protocol, +13). b. 
and e. Percentage of Tuj1+ cells among total DAPI in 100 images acquired for the chosen 
concentration at 13 days, respectively plated 2 and 7 days after 4-OHT treatment. Means +/- SEM 
are reported. c. and f. Average neurite length per neuron, generated starting from MEFs plated, 
respectively, 2 and 7 days after 4-OHT treatment, calculated with Neuritetracer. Means +/- SEM 
are reported. Representative experiments are reported. d. Cell mortality reported as the ratio 
between the sum of DAPI calculated 1 day after doxycycline administration at the chosen 
concentration (DAPI start) and the sum of DAPI of the corresponding chamber at 13 days (DAPI 
end) of MEFs plated 2 (on the left) and 7 (on the right) days (2d and 7d) after 4-OHT treatment. 
Means +/- SEM are reported. *** p<0.0001; ** p<0.001; *p<0.01; ns not significant p>0.01. 
 
Moreover if knock-out MEFs were left in culture one additional week before transduction 
with BAM factors, mortality rate was not affected (Figure 15d on the right and 16e) as also 
demonstrated by the comparison of absolute counts of experimental condition and control 
at the same time points of FACS analysis (Figure 16f). 
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Figure 16: Transdifferentiation in the absence of MLL2: FACS experiments 
a. Percentage of PSA-NCAM+ cells 5, 7, 9 and 13 days after plating, assayed with FACS analysis. 
MEFs were plated for transdifferentiation 2 days after the end of 4-OHT treatment. Means +/- SEM 
are reported. Mll1+/+ Mll2+/+ n=1 at day 0, 7 and 9, n=4 at day 5 and 13; Mll2-/- n=1 at day 0, 7 and 9, 
n=3 at day 5 and 13. b. The percentage of PSA-NCAM+ cells 5, 7, 9 and 13 days after plating, 
assayed with FACS analysis, is reported for one representative experiment. MEFs were plated for 
transdifferentiation 7 days after the end of 4-OHT treatment. Means +/- SEM are reported. Mll1+/+ 
Mll2+/+ n=1; Mll2-/- n=2. c. Percentage of YFP+ cells in the PSA-NCAM+ population assayed with 
FACS analysis 5, 7, 9 and 13 days after plating. MEFs were plated for transdifferentiation 7 days 
after the end of 4-OHT treatment. Means +/- SEM are reported. Mll1+/+ Mll2+/+ n=2; Mll2-/- n=2. d. 
Mortality rate as percentage of PI+ cells 5, 7, 9, 13 and 21 days after plating, assayed with FACS 
analysis. MEFs were plated for transdifferentiation 2 days after the end of 4-OHT treatment. Means 
+/- SEM are reported. Mll1+/+ Mll2+/+ n=1 at day 0, 7 and 9, n=4 at day 5 and 13; Mll2-/- n=1 at day 
0, 7 and 9, n=3 at day 5 and 13. e. Mortality rate as percentage of PI+ cells 5, 7, 9, 13 and 21 days 
after plating, assayed with FACS analysis, in one representative experiment. MEFs were plated for 
transdifferentiation 7 days after the end of 4-OHT treatment. Means +/- SEM are reported. Mll1+/+ 
Mll2+/+ n=1; Mll2-/- n=2.  f. The total number of cells was calculated 5, 7, 9 and 13 days after plating 
with the Countess Automated Cell Counter. The percentage of dead cells was calculated over the 
initial number of plated MEFs. One representative experiment is reported with means +/- SEM. 
MEFs were plated for transdifferentiation 7 days after the end of 4-OHT treatment. Mll1+/+ Mll2+/+ 
n=1; Mll2-/- n=2.  
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In the ScanR experiments where MEFs were immediately plated after 4-OHT treatment, 
transdifferentiation efficiency did not decrease in any of the 2 experiments (Figure 17a on 
the left). When the efficiency rate was calculated by FACS, using the same experimental 
timeline of ScanR experiments, an initial decrease in PSA-NCAM+ cells was observed, 
which was later overcome at 13 days (the time point analysed by ScanR) (Figure 16a). 
Indeed, the efficiency of transdifferentiation was higher in Mll2-/- than Mll2+/+, such as in 
ScanR experiments (Figure 17b on the left), but knock-out cells still proliferated after 
doxycycline administration (Figure 17c). 
If MEFs were instead plated one week after 4-OHT treatment, we observed a lower 
transdifferentiation efficiency of Mll2-/- MEFs than Mll2+/+ both in ScanR and FACS 
analyses (Figures 17a on the right and 17b on the right). The initial lower percentage of 
PSA-NCAM+ Mll2-/- iNs was maintained throughout the entire transdifferentiation process 
and was not overcome even 13 days after plating (Figure 16b). Moreover we can exclude 
that Mll2-/- cells were counterselected, since at 13 days the majority of iNs in the 
experimental and control conditions were YFP+, which is expressed only upon Cre-
mediated removal of the stop cassette upstream to the yfp gene (Figure 16c).  Hence YFP 
positivity can be exploited as an indirect surrogate marker to assess the percentage of 
recombined cells throughout transdifferentiation. 
One possible explanation for the observed discrepancy among the results of the two 
experimental set-ups is the following: in the case of MEFs immediately plated after 4-OHT 
treatment there could be a residual level of MLL2 protein and of H3K4me3 at its gene 
targets, respectively degraded (as confirmed by western blot) and erased/diluted if waiting 
for one additional week. To test this hypothesis the western blot for MLL2 has to be 
performed immediately after 4-OHT treatment. 
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Figure 17: Transdifferentiation efficiency in the absence of MLL2 
Efficiency of transdifferentiation in ScanR and FACS experiments. a. The number of Tuj1+ cells 
for the chosen concentration was calculated and related to the number of DAPI quantified 1 day 
after doxycycline administration. On the left the experiments with MEFs plated 2 days after 4-OHT 
treatment (2d) and on the right with MEFs plated 7 days after 4-OHT treatment (7d). Means +/- 
SEM are reported.b. Efficiency of transdifferentiation calculated as the percentage of PSA-NCAM+ 
iNs cells at 13 days with respect to the number of plated cells. On the left the experiments with 
MEFs plated 2 days after 4-OHT treatment (2d) (Mll1+/+ Mll2+/+ n=4; Mll2-/- n=3) and on the right 
with MEFs plated 7 days after 4-OHT treatment (7d) (Mll1+/+ Mll2+/+ n=9; Mll2-/- n=7). Means +/- 
SEM are reported.*** p<0.0001; ** p<0.001; *p<0.01; ns not significant p>0,01. c. Absolute cell 
number, evaluated through the Countess Automated Cell Counter, of Mll2-/- (n=2) and 
Mll1+/+Mll2+/+ (n=3), 5 and 13 days after plating for transduction. MEFs were left in normal 
medium 2 days after 4-OHT treatment, before they were plated for transdifferentiation. Means +/- 
SEM are reported. 
 
In 3 out of 3 experiments, independently of whether MEFs were plated 2 or 7 days after 4-
OHT treatment and with different levels of affection, neurite elongation was impaired in 
Mll2-/- iNs with respect to control (Figures 15c, 15f and 18a). Despite this the Mll2-/- iNs, 
a	 b	
c	
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in a preliminary experiment, were positive for MAP2b and NeuN, more mature neuronal 
markers (Figures 18 b and c). 
 
                           
 
Figure 18: The absence of Mll2 impairs iNs morphology 
a. Representative images of Mll1+/+ Mll2+/+ (upper panels) and Mll2-/- (lower panels) iNs (DAPI is 
in blue and Tuj1 in red) at 13 days. b. Representative images of Mll1+/+ Mll2+/+ (upper panel) and 
Mll2-/- (lower panel) iNs (DAPI is in blue, Tuj1 in red, NeuN in green) at 13 days. c. 
Representative images of Mll1+/+ Mll2+/+ (upper panel) and Mll2-/- (lower panel) iNs (DAPI is in 
blue, Doublecortin in red, MAP2b in green) at 13 days. 
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7.4 Lack of both MLL1 and MLL2 severely impairs 
transdifferentiation 	
Since MLL1 and MLL2 are two homolog proteins, to better characterize specific functions 
not visible in the single knock-out because of the compensation of the other methylase, we 
also studied the transdifferentiation of Mll1-/-Mll2-/- MEFs. This strategy allowed the 
investigation of the overall role of the MLL1-MLL2 COMPASS-like complexes during the 
direct conversion MEFs-to-iNs. As in the case of transdifferentiation of Mll1-/- and Mll2-/- 
MEFs, also for the double knock-out I performed both the assessment of the 
transdifferentiation efficiency and the morphological analysis of Mll1-/-Mll2-/- iNs through 
ScanR and FACS. In particular ScanR-based experiments were carried out on MEFs plated 
immediately after 4-OHT treatment, while the FACS experiment on MEFs plated one 
week later, to ensure the degradation of the two methylases and the erasure of the 
H3K4me3 mark, deposited prior to Cre activity induction. 
During 4-OHT treatment, no difference in cell death was detected between Mll1-/-Mll2-/- 
and control MEFs (Figures 19a and 19b). However upon infection with BAM factors and 
their induction with doxycycline, cell vitality massively dropped in the double knock-out 
MEFs both in ScanR and FACS experiments (Figures 20a, 20d and 20e).  
 
 
Figure 19: MEFs vitality upon deletion of both Mll1 and Mll2 
a	 b	
		 87	
a. The total number of cells was calculated 2, 5 and 9 days after the first 4-OHT administration 
with the Countess Automated Cell Counter. Means +/- SEM are reported. Mll1+/+ Mll2+/+ n=5; Mll1-
/-Mll2-/-  n=3. b. Mortality rate as percentage of PI+ cells 2, 5 and 9 days after the first 4-OHT 
administration. Means +/- SEM are reported. Mll1+/+ Mll2+/+ n=5; Mll1-/-Mll2-/-  n=3.  
 
The initial decrease in the percentage of iNs generated was maintained until the last time 
point analysed (13 days) both in FACS and ScanR (Figures 20c and 20f).  
 
	
Figure 20: Transdifferentiation in the absence of both MLL1 and MLL2 
a. Cell mortality reported as the ratio between the sum of DAPI calculated 1 day after doxycycline 
administration at the chosen concentration (DAPI start) and the sum of DAPI of the corresponding 
chamber at 13 days (DAPI end) in 2 independent experiments (exp1 on the left and exp2 on the 
right). b.  Efficiency of transdifferentiation of ScanR experiments (exp1 on the left and exp2 on the 
right). The number of Tuj1+ cells for the chosen concentration was calculated and related to the 
number of DAPI quantified 1 day after doxycycline administration. c. Percentage of Tuj1+ cells 
among total DAPI in 100 images acquired for the chosen concentration at 13 days. One 
representative experiment is reported showing also means +/- SEM. d. The total number of cells 
was calculated 5, 7, 9 and 13 days after plating with the Countess Automated Cell Counter. The 
percentage of dead cells was calculated over the initial number of plated MEFs.  Means +/- SEM 
are reported. Mll1+/+ Mll2+/+ n=3; Mll1-/-Mll2-/-  n=3. e. Mortality rate as percentage of PI+ cells 5, 7, 
9 and 13 days after plating, assayed with FACS analysis. Means +/- SEM are reported. Mll1+/+ 
a	
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b	
e	 f	
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Mll2+/+ n=3; Mll1-/-Mll2-/-  n=3. f. Percentage of PSA-NCAM+ cells 5, 7, 9 and 13 days after plating, 
assayed with FACS analysis. Means +/- SEM are reported. Mll1+/+ Mll2+/+ n=3; Mll1-/-Mll2-/-  n=3. 
*** p<0.0001; ** p<0.001; *p<0.01; ns not significant p>0.01. 
 
The transdifferentiation efficiency in Mll1-/-Mll2-/- resulted very low both in ScanR (2 out 
of 2 independent experiments) (Figure 20b) and in FACS experiments (Mll1-/-Mll2-/- n=3 
batches of MEFs derived from different embryos; Mll1+/+Mll2+/+ n=3 batches of MEFs 
derived from different embryos) (Figure 21c). Moreover the few iNs generated presented 
very short neurites (Figures 21a and 21b). 
 
	
Figure 21: The absence of Mll1 and Mll2 highly affects transdifferentiation 
a. Representative images of Mll1+/+ Mll2+/+ (upper panels) and Mll1-/- Mll2-/- (lower panels) iNs 
(DAPI is in blue and Tuj1 in red) at 13 days. b. Average neurite length per neuron calculated with 
Neuritetracer. Means +/- SEM are reported. c. Efficiency of transdifferentiation calculated as the 
percentage of PSA-NCAM+ iNs cells at 13 days with respect to the number of plated cells. Means 
+/- SEM are reported. Mll1+/+ Mll2+/+ n=9; Mll1-/- Mll2-/- n=3. *** p<0.0001; ** p<0.001; *p<0.01; 
ns not significant p>0.01. 
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7.5 Comparison of transdifferentiation efficiency across the 
different genotypes 	
If we pooled the transdifferentiation analysis of Mll1-/-, Mll2-/-, Mll1-/-Mll2-/- and 
Mll1+/+Mll2+/+ MEFs, in FACS experiments Mll1-/- showed a reduction in 
transdifferentiation efficiency (Figure 22d), accompanied, however, by a mortality rate 
higher than Mll1+/+Mll2-+/+ transdifferentiating MEFs (Figure 22b). In the case of ScanR-
experiments, instead, Mll1-/- MEFs immediately plated presented the same mortality rate 
and transdifferentiation efficiency of Mll1+/+Mll2+/+ and Mll1+/- transdifferentiating MEFs 
(Figure 23a). While this excludes that Mll1 is haploinsufficient for cell fate reassignment, 
it also suggests that one additional week in culture before plating the MEFs for 
transdifferentiation might be necessary to eliminate any residual MLL1 protein and hence 
expose the full impact of its depletion. Therefore the choice of plating the MEFs for 
transdifferentiation 2 or 7 days after 4-OHT treatment could explain the differences in cell 
mortality and in transdifferentiation efficiency between the two experimental strategies. 
Indeed, by FACS (in which MEFs were plated 7 days after 4-OHT), the efficiency resulted 
reduced for Mll1-/- MEFs (Figure 22d). Alternatively, we hypothesised that the prolonged 
absence of MLL1 could severely affect cell cycle/cell viability already at the MEFs state. 
Hence the observed defects could be the consequence of the highly compromised starting 
cells and not of the role of MLL1 during the transdifferentiation process per se (Figure 
22b). Therefore, the reduction we observed in transdifferentiation efficiency should be 
only the consequence of lower cell viability in Mll1-/- MEFs. 
Both in ScanR and FACS analysis, instead, the mortality rate of Mll2-/- transdifferentiating 
MEFs was the same as in the control ones (Figures 22b and 23a). Hence the observed 
reduction in transdifferentiation efficiency is indicative of the role of MLL2 specifically 
during transdifferentiation (Figures 22d and 23b). 
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Mll1-/- Mll2-/- MEFs presented the highest cell death rate (Figures 22b and 23b) and the 
lowest transdifferentiation efficiency (Figures 22d and 23a). In particular, in the FACS 
analysis, the percentage of dead cells was the same of the one of Mll1-/- transdifferentiated 
MEFs (Figure 22b), but the transdifferentiation efficiency was lower (Figure 22d). This 
underlines that MLL2 is the main MLL1-MLL2- COMPASS-like member involved in cell 
conversion and that it does not play a role in cell viability. 
Finally, pooling all FACS experiments together, we observed that throughout 
transdifferentiation the Mll1-/- Mll2-/- condition had the lowest percentage of PSA-NCAM+ 
cells of all; this percentage was slightly higher in Mll2-/-, while Mll1-/- and Mll1+/+ Mll2+/+ 
possessed similarly high percentages of iNs (Figure 22a). Moreover the defective 
morphology of Mll2-/- iNs was maintained up to day 21 (Figure 23c). 
The comparison of transdifferentiation efficiency across different genotypes confirms that, 
while the absence of Mll1 only impairs cell viability, the knock-out of Mll2 impinges on 
the efficiency of direct cell conversion. MLL2 is therefore the main MLL1-MLL2 
COMPASS-like member recruited during transdifferentiation. Indeed, the double knock-
out, despite having the same cell death rate of Mll1-/- transdifferentiating MEFs, showed 
the lowest transdifferentiation efficiency, further underpinning a role for H3K4 MLL2-
deposited trimethylation during transdifferentiation. 
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Figure 22: Comparison of transdifferentiation efficiency in all conditions: FACS analysis 
a. The percentage of PSA-NCAM+ cells 5, 7, 9 and 13 days after plating, assayed with FACS 
analysis, is reported for Mll1+/+Mll2+/+, Mll1-/-, Mll2-/- and Mll1-/-Mll2-/- transdifferentiating MEFs. 
Means +/- SEM are reported. b. The total number of cells was calculated 13 days after plating with 
the Countess Automated Cell Counter. The percentage of dead cells 13 days was calculated over 
the initial number of plated MEFs. Means +/- SEM are reported. c. Numbers of Mll1+/+ Mll2+/+, 
Mll1-/-,  Mll2-/- and Mll1-/-Mll2-/- samples analysed for time point. The number of samples analysed 
in b. and d. corresponds to the day 13th. d. Efficiency of transdifferentiation calculated as the 
percentage of PSA-NCAM+ iNs cells at 13 days with respect to the number of plated cells. Means 
+/- SEM are reported.  *** p<0.0001; ** p<0.001; *p<0.01; ns not significant p>0.01.  
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Figure 23: Comparison of transdifferentiation efficiency in all conditions: ScanR analysis 
a. Cell mortality reported as the ratio between the sum of DAPI calculated 1 day after doxycycline 
administration at the chosen concentration (DAPI start) and the sum of DAPI of the corresponding 
chamber at 13 days (DAPI end). Means +/- SEM are reported. 2d: MEFs plated 2 days after 4-OHT 
treatment; 7d: MEFs plated 7 days after 4-OHT treatment. b.  Efficiency of transdifferentiation in 
ScanR experiments. The number of Tuj1+ cells for the chosen concentration was calculated and 
related to the number of DAPI quantified 1 day after doxycycline administration. Means +/- SEM 
are reported. 2d: MEFs plated 2 days after 4-OHT treatment; 7d: MEFs plated 7 days after 4-OHT 
treatment.  c. Numbers of Mll1+/+ Mll2+/+, Mll1-/-,  Mll2-/- and Mll1-/-Mll2-/- samples analysed in 
graphs b. and d. 2d: MEFs plated 2 days after 4-OHT treatment; 7d: MEFs plated 7 days after 4-
OHT treatment. d. Representative images of 21 days Mll1+/+Mll2+/+ (left panel), Mll1-/-, (middle 
panel) and Mll2-/- (right panel) iNs acquired at the bright field microscope. 	
 
7.6 Transcriptomic and epigenomic analysis set-up 	
To dissect how MLL2 modulates the epigenome and trascriptome resetting in order to 
enable transdifferentiation, a comparative transcriptomic and epigenomic analysis between 
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the experimental and control conditions was performed. We established the 5th and the 13th 
day after BAM factors transduction as the time points where to execute, respectively 
Chromatin Immunoprecipitation coupled to deep sequencing (ChIP-seq) for H3K4me3 and 
MENIN (5th day) and ChIP-seq for H3K4me3 and RNA-sequencing (RNA-seq) (13th day) 
(Figure 24). We selected the 5th day of transdifferentiation because at this stage MEFs have 
been cultured already 1 day in neuronal medium and 3 days have elapsed since the 
induction of the BAM factors. Hence transdifferentiating MEFs should be at the peak of 
the cell conversion process and therefore of epigenome resetting. Accordingly, at day 5 
transdifferentiating MEFs, infected with Ascl1 only, still do not express Tau-EGFP+, but 
they are actively changing toward neuronal identity108. Only ~10% of Mll2-/- cells is PSA-
NCAM+ at day 5 (Figure 22a) and we assumed that all the infected MEFs are equally 
competent to transdifferentiate at this stage108. Hence we performed the ChIP on the entire 
population of transdifferentiating MEFs.  
As previously described, transdifferentiation does not have 100% efficiency. Therefore, at 
13 days, iNs have to be separated from non-transdifferentiated MEFs for RNA-seq and 
ChIP-seq analyses. Moreover neurons are fragile cells for which sorting represents a major 
stress. Hence we performed an extensive set-up to allow the retrieval of good 
quantity/quality RNA and chromatin from pure populations of iNs. 
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Figure 24: Experimental outline for the dissection of MLL2 role 
After leaving 4-OHT-treated MEFs 7 days in medium not supplemented with 4-OHT, ChIP-seq 
was performed 5 and 13 days after plating. These time points were chosen because at 5 days cells 
are equi-competent to become iNs and are actively resetting their epigenomes. At day 13, instead, 
iNs were separated from non-transdifferentiated MEFs by FACS sorting and ChIP-seq was 
executed. In particular, at day 5 I performed the ChIP-seq for H3K4me3 and MENIN and at day 13 
the ChIP-seq for H3K4me3. 
 
I did a first pilot sorting for PSA-NCAM+ cells 7 days after plating. At this time point 
neurites are not elongated and therefore iNs should be less fragile. The goal was then to 
replate the pure population of sorted iNs and to extract RNA 7 days later (13 days after the 
MEFs plating for transdifferentiation, the time point used for all the analyses). However, 
almost all sorted cells died few days after plating. 
Afterwards an extensive screening was performed to choose the detaching reagent less 
stressful for iNs. The final protocol provided sorting at 13 days after plating and the use of 
Accutase as detaching reagent. Accutase was selected because it allows, in 2-3 minutes, to 
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have all the adherent cells detached with relatively low mortality. To retrieve at least 100 
ng of RNA and enough chromatin (i.e., 100 µg), 107 cells were plated for 
transdifferentiation. 
 The gating strategy is reported in Figure 25a. The samples from which RNA was extracted 
and chromatin cross-linked had a purity of around 90% (Figure 25b). In the case of RNA-
seq, after the collection of the positive fraction of each sample, RNA was immediately 
extracted with RNeasy micro kit (to obtain RNA with the level of purity required for RNA-
seq) and stored at -80 °C. Extracted RNA presented both an RNA integrity number (RIN) 
close to 10 and a good rRNA Ratio (28s/18s) (Figure 25c). In the case of ChIP, as soon as 
the positive fraction was collected, iNs were immediately fixed.			
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Figure 25: Sorting of PSA-NCAM+ fraction and RNA extraction for RNA-seq 
a. Gating strategy used for sorting: doublets/ physical parameters/ PSA-NCAM positive cells. 
Unstained sample (upper panel); stained sample (lower panel). b. Analysis of purity post sorting. c. 
RNA analysis at Bioanalyzer. Two representative Mll1+/+Mll2+/+ (upper panels) and two Mll2-/- 
(lower panels) RNA samples, extracted from different embryos, are shown. 					
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7.7 RNA-seq analysis 	
RNA-seq was performed on 5 Mll2+/+ (ctrl_1, ctrl_3, ctrl_6, ctrl_I15, ctrl_I17) and 5 Mll2-/- 
(KO_11, KO_17, KO_F16, KO_F11, KO_E10) PSA-NCAM+ iNs derived from 10 
different embryos, sorted at day 13. In particular, in order to discriminate sex-linked 
differences, we included 3 males and 2 females Mll2+/+ transdifferentiating MEFs and 4 
males and 1 female Mll2-/- MEFs. We sequenced each sorted sample with a coverage of 
120 millions of reads at a read length of 100 bp, paired end. Since the H3K4me3 has been 
associated with alternative splicing142-145, with this setup we could determine also if some 
genes were differentially spliced in the absence of Mll2. 
The unsupervised clustering of the transcriptomes showed a clear distinction between Mll2-
/- and control iNs samples (Figure 26a). Hence, although this analysis comprises two 
different RNA-seq rounds (i.e., two different infections and sortings), iNs did not show 
signs of a batch effect. 
With a false discovery rate (FDR) < 0.01 and a fold change (FC) > 1.5, 1828 genes 
resulted differentially expressed between Mll2+/+ and Mll2-/- iNs and the majority of them 
were down-regulated in the latter, consistently with a gene activator function of MLL2 
(Figure 26b). 
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Figure 26: RNA-seq analysis of Mll2+/+ and Mll2-/- iNs 
a. Principal component analysis (PCA) of Mll2+/+ and Mll2-/- iNs before (upper graph) and after 
(lower graph) genes normalization. b. Heat map of the differentially expressed genes between 
Mll2+/+ and Mll2-/- iNs with a FDR < 0.01 and a FC > 1.5. The colour scale (-2 blue to +2 red) 
represents Z-Score. Mll2+/+: ctrl_1, ctrl_3, ctrl_6, ctrl_I15, ctrl_I17; Mll2-/-: KO_11, KO_17, 
KO_F16, KO_F11, KO_E10. 
 
Moreover Magohb, the best characterize MLL2-exclusive target so far64, was down-
regulated in Mll2-/- iNs, confirming the absence of a counterselection during the 14 days of 
transdifferentiation (Figure 27c). The B-cell lymphoma 2 (Bcl2) was down-regulated in 
Mll2-/- iNs as in ESCs84, but the Bcl-2 associated X protein (Bax) and the Bcl-2 associated 
agonist of cell death (Bad) had similar level of expression between knock-out and control 
iNs (Figure 27e). 
In Mll2-/- iNs Mll2 was not down-regulated, both in RNA-seq (Figure 27a on the left) and 
in real time quantitative PCR (RT-qPCR) (Figures 27b and 27d), pointing to the lack of its 
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degradation by nonsense-mediated decay. Moreover, Mll1 and menin were not up-
regulated to compensate for the absence of Mll2 (Figure 27a). 
 
 
 
Figure 27: RNA level of MLL1-MLL2 COMPASS-like subunits, of Magohb and of apoptosis 
related genes 
a. Fragments Per Kilobase of exon per Million fragments mapped (FPKM) of Mll2, Mll1 and 
menin in RNA-seq analysis. Means and Standard Deviation (SD) are reported. b. Mll2 RNA level 
of sorted iNs at 13 days, assayed by RT-qPCR. Means and SD are reported. Mll1+/+Mll2+/+ n=2; 
Mll2-/- n=1. c. FPKM of Magohb in RNA-seq analysis. Means and SD are reported. d. Mll2 RNA 
iNs	13	days	
transdiﬀeren/a/ng	
MEFs	5	days	
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level in transdifferentiating MEFs at 5 days assayed by RT-qPCR. Means + SD are reported.  
Mll1+/+Mll2+/+ n=1; Mll2-/- n=2. e. FPKM of Bcl2, Bax and Bad in RNA-seq analysis.  Means and 
SD are reported.   
* FDR <0.01; ns not significant p>0.01. 
 
Among the 10 genes, already reported by Wapinski and colleagues to be induced to guide neuronal 
transdifferentiation106, 6 were repressed in Mll2-/- iNs in a statistically significant manner (Figure 
28a).  
 
 
Figure 28: RNA level of neuronal induced genes 
FPKM of genes reported to be induced during transdifferentiation by Wapinski and colleagues106. 
Means and SD are reported. * FDR <0.01. 
 
Recently, the network of genes involved in transdifferentiation has begun to be 
elucidated108. In particular a subdivision has been proposed between the MEF subnetwork, 
the initiation subnetwork and the maturation subnetwork, based on the stage of cell fate 
conversion that the genes regulate (Figure 29a). When we analysed the behaviour of these 
genes in our RNA-seq analysis, only 3 out of ~30 genes belonging to the MEFs 
subnetwork (Figure 29c) and 3 out of ~25 genes belonging to the initiation subnetwork 
were misregulated (Figure 29e), while 7 out of 25 genes of the maturation subnetwork 
were down-regulated, and 1 up-regulated, in Mll2-/- iNs with respect to control (Figure 
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29g). In particular, the 3 genes involved in the MEFs subnetwork were down-regulated in 
Mll2-/- iNs, suggesting that MLL2 is, directly or indirectly, necessary for their up-
regulation. On the contrary the 3 genes of the initiation subnetwork had an opposite trend 
from the one published by Wernig and colleagues. Indeed Maf, up-regulated at 13 days 
(Figure 29d on the left) had lower expression in Mll2-/- iNs than in controls (Figure 29e on 
the left), while Tsdp2 and Zfp238, both down-regulated at 13 days (Figure 29d in the 
middle and on the right), were more highly expressed in Mll2-/- iNs than in controls (Figure 
29e in the middle and on the right). This was the case also for Insm1, down-regulated at 13 
days (Figure 29f). Therefore the analysis showed that the genes of the maturation 
subnetwork were the most affected in the absence of MLL2 and that the down-regulation 
of a repressor in Mll2-/- iNs could be the cause of the observed up-regulation of specific 
genes. 
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Figure 29: Misregulation of transdifferentiation subnetworks 
a. Modified image from Treutlein et al., Nature 2016108. b. Reads per Kilobase per Million mapped 
reads (RPKM), during transdifferentiation, of the 3 genes of the MEFs subnetwork down-regulated 
in Mll2-/- iNs. Means and SD are reported. Source data: Wapinski et al., Cell 2013106. c. FPKM of 
the 3 genes of the MEFs subnetwork down-regulated in Mll2-/- iNs in our RNA-seq at 13 days. 
Means and SD are reported. d. RPKM of the 3 genes of the initiation subnetwork, misregulated in 
Mll2-/- iNs, during transdifferentiation. Means and SD are reported. Source data: Wapinski et al., 
a	
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Cell 2013106. e. FPKM of the 3 genes of the initiation subnetwork, misregulated in Mll2-/- iNs, in 
our RNA-seq at 13 days. Means and SD are reported. f. RPKM during transdifferentiation of the 
Insm1, the only misregulated gene of the maturation subnetwork, up-regulated in Mll2-/- iNs. 
Means and SD are reported. Source data: Wapinski et al., Cell 2013106. g. FPKM of the 8 genes of 
the maturation subnetwork misregulated in Mll2-/- iNs in our RNA-seq at 13 days. Means and SD 
are reported. * FDR <0.01. 
 
When we analysed the top 30 most differentially expressed genes, which stood out for their 
statistical significance and/or for their FC, as expected, the majority of them were down-
regulated in Mll2-/- iNs and related to neuronal function (Figure 30). 
 
 
Figure 30: Top 30 differentially expressed genes 
Volcano plot of the differentially expressed genes, in Mll2-/- with respect to control, with a FDR 
<0.01 and a FC > 0.5. 
 
5 out of 30 genes promote physiological neurite extension, in accordance with the main 
defect observed in Mll2-/- iNs. The Protein phosphatase 1 regulatory subunit 9A (Ppp1r9a) 
or Neurabin-I, is a neuronal specific-F-actin binding protein important for neurite 
outgrowth and dendritic spine formation, hence crucial both at precocious and late stages 
of neuronal maturation. Its deletion impairs cortical and hippocampal neuron projection 
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elongation146-148, in line with our results. Also Myosin 16 (Myo16), which belongs to 
Neuronal tYrosine-phosphorylated Adaptor for the PI 3-kinase (NYAP)	phosphoproteins 
family, favours neuritogenesis through the interaction with the	 WASP-family verprolin 
homologous protein (WAVE) complex and the Phosphatidylinositol 3 (PI3) kinase149,150. 
Calsyntenin 3 (Clstn3) is involved in both excitatory and inhibitory axon presynaptic 
organization. Mice Clstn3-/- present a reduction in synapse density151. Moreover both 
MYO16 and CLSTN3 interact with NEUREXIN-1151,152, also down-regulated in Mll2-/- iNs 
(Figure 31b), fundamental for synapse differentiation and transmission. The Leucine-rich 
repeat and fibronectin type III domain-containing protein 1 (Lrfn1), and to a lower extent 
the other family members Lrfn3 and Lrfn5, are genes down-regulated in the knock-out 
(Figure 31c) (their trend during transdifferentiation is reported in Figure 31a), that by 
similarity of the domains they encode have been associated with neurite outgrowth153. 
Finally the type I-beta regulatory subunit of protein kinase A (Prka1b) has been linked to 
neurophilament phosphorylation, the main axon cytoskeleton components154,155. 
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Figure 31: Differentially expressed genes involved in synapse and neurite formation 
a. RPKM, during transdifferentiation, of the genes of Lrfn family. Means and SD are reported. 
Source data: Wapinski et al., Cell 2013106. b. FPKM of Nrxn1 in our RNA-seq at 13 days. Means 
and SD are reported. c. FPKM of Lrfn family members in our RNA-seq at 13 days. Means and SD 
are reported. d. FPKM of Jph3 in our RNA-seq at 13 days. Means and SD are reported. * FDR 
<0.01. 
 
8 genes were linked to synapse formation and neurotransmission. JUNCTOPHILIN 4 
(Jph4) and Jph3 (Figure 31d) are the two brain-specific proteins involved both in the 
formation of complexes between the plasma membrane and the endo-sarcoplarmatic 
reticulum (i.e., subsurface cisternae) and in the synaptic plasticity156. Synaptophysin (syp) 
encodes for a synaptic vescicle transmembrane protein, important for synaptic vescicle 
endocytosis157 and SYNAPTOBREVIN (i.e., a synaptic vescicle transmembrane protein, 
important for synaptic vescicle exocytosis) retrieval158. Mice syp-/- do not show 
neurotransmission defects159, but their learning and memory are altered160. The absence of 
a clear synaptic transmission phenotype is attributed to the compensation of other synaptic 
vescicles proteins: the SYNAPTOPORIN and the SYNAPTOGYRINS (syngr1-4). 
Interestingly, among synaptogyrins, only syngr1 and syngr3 are up-regulated as long as 
transdifferentiation process progresses106 (Figure 32b) and they were both down-regulated 
in Mll2-/- iNs (Figure 32a).  
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Figure 32: Synaptogyrins 
a. FPKM of Synaptogyrin (Syngr) genes in our RNA-seq at 13 days. Means and SD are reported.  
b. RPKM, during transdifferentiation, of the genes of Syngr family. Means and SD are reported.  
Source data: Wapinski et al., Cell 2013106.*FDR <0.01. 
 
The sulfotransferase family 4A member 1 (Sult4a1) is associated with schizophrenia, since 
it is located in a region often deleted in schizophrenic patients161 and is believed to possess 
a role in neurotransmitter metabolism. The protein tyrosine phosphatase receptor type N 
(PTPRN) or insulinoma associated protein 2 (IA-2) is a membrane-associated vescicular 
protein that, despite being one of the main type 1 diabetes autoantigens, is involved in 
neurotransmitter release162 and in the nervous system it is mainly localized in neurites163. 
Cell adhesion molecule 3 (Cadm3) belongs to the immunoglobulin-like family and it is 
important for the synapse formation and also for myelinisation and axon bundles164. Type-1 
adenylyl cyclase (Adcy1) is fundamental for memory formation, coupling Ca2+ release to 
cyclic AMP. Finally the glutamate ionotropic receptor NMDA type subunit 2B (Grin2b) 
encodes, as the acronym states, for the subunit with the agonist binding site of the NMDA 
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receptor, while the ACHETYLCOLINESTERASE (Ache) hydrolyzes the neurotransmitter 
acetylcolin. 
The programmed cell death 5  (Pdcd5) is a gene whose level increases during apoptosis165. 
Moreover the knock-down of Pdcd5 reduces the apoptosis rate166. Hence its down-
regulation in Mll2-/- iNs further confirms their lower cell death. 
The majority of the other genes are poorly characterized in literature and few of them are 
without a clear relation with the observed phenotype. 
Using as a guiding criterion the gene ontology (GO) analysis we chose for validation 14 
genes linked to neuronal maturation and with a high Fragments Per Kilobase of exon per 
Million fragments mapped (FPKM), but after several trials only for 5 of them (Figures 28, 
29e and 33a) I was able to find primers with a good efficiency of amplification. The 
residual precious RNA was spared to validate the targets coming out from the integrated 
analysis with the H3K4me3 ChIP-seq. In particular we analysed Zfp238 and Syt1, 
fundamental during the establishment of transdifferentiation subnetworks (Figures 28 and 
29d), Ptprn, one of the highest differentially expressed genes (Figure 30) and the 
apolipoptrotein E (ApoE), that, besides having a role in Alzheimer disease, has been 
involved in neurite extension167,168. Also the Kinesin family member 5A (Kif5a) was chosen 
for its role in neurite outgrowth169. In all the analysed genes the reduction was confirmed 
but only 2 of them were statistically significant (Figures 33b-f). Zfp238, one of the main 
down-stream effectors of ASCL1106 was confirmed to be higher in Mll2-/- iNs (Figure 33b). 
We also analysed its level 5, 9 and 13 days after MEFs were plated for transdifferentiation, 
in unsorted cells in two independent experiments observing that this Ascl1-effector was 
highly induced at 5 days in Mll2+/+ cells and lowly repressed at 13 days in Mll2-/- cells 
(Figure 33h). 
		 108	
 
 
Figure 33: RNA-seq validation 
a. FPKM of the genes chosen for validation. Means and SD are reported. *FDR <0.01. b. to f. 
RNA level of the genes chosen for validation assayed by qPCR. Means and SD are reported.  *** 
Zfp238	
Ptprn	 ApoE	
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p<0.0001; ** p<0.001; *p<0.01. g. Zfp238 RNA level in unsorted cells 5, 9 and 13 days after 
plating, assayed by RT-qPCR. Means and SD are reported. The two graphs represent 2 independent 
experiments. On the left Mll1+/+Mll2+/+ n=1, Mll2-/- n=2. On the right Mll1+/+Mll2+/+ n=2, Mll2-/- 
n=2. 
 
Hence, in the absence of MLL2, the process of transdifferentiation starts, but the networks 
are misregulated, as confirmed by the level of Zfp238 and of all the aforementioned genes. 
Moreover several differentially expressed genes are involved in neurite extension, the main 
defect observed in Mll2-/- iNs. 
 
7.8 Differential splicing 
 
Among the top 30 differentially expressed genes the Serine/Arginine-Rich Splicing Factor 
12 (Srsf12) was present, further suggesting that splicing might be affected (Figure 30). In 
particular SRSF12 induces distal 5’ splicing sites and functions as a repressor of canonical 
Serine Arginine rich proteins170. 
We found 7 genes subjected to differential exons usage in Mll2-/- with respect to the 
control PSA-NCAM+ iNs.  By this analysis Mll2 came out as differentially spliced at exon 
2, confirming the lack of MLL2 in knock-out iNs and therefore the absence of any 
counterselection for Mll2+/+ MEFs that could have survived through the end of 4-OHT 
treatment (Figure 34). 
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Figure 34: Mll2 exon 2 deletion 
In the top graph Mll2 exon usage in Mll2-/- and Mll1+/+Mll2+/+ iNs. In the middle graph normalized 
read counts. In the bottom graph schematic of the differentially used exons. The statistically 
significant ones are in purple. Mll2-/- is in blue and Mll1+/+Mll2+/+ in red. 
 
The ArfGAP with GTPase domain, ankyrin repeat and PH domain 2	 (Agap2) possesses 
two known isoforms (Figure 35d). The first isoform (i.e., NM_001033263) is brain-
specific and negatively associated with neuronal apoptosis through the interaction with 
Phosphatidylinositol 3 (PI3) kinase. Recently it was also demonstrated to be involved in 
neurite outgrowth171. The isoform 2 (i.e., NM_001301014), instead, prevents apoptosis by 
interacting with Akt. In our datasets we detected only the isoform 1, that, moreover, is 
significantly down-regulated in Mll2-/- iNs (Figure 35b). The Mll2-/- Agap2 transcript 
presented a lower usage of exon 7, encoding for part of the small GTPase domain, while 
the Mll2+/+ Agap2 transcript showed a lower usage of exon 19, containing part of the 
ankyrin-repeat containing domain, a protein-protein interaction domain (Figures 35a and 
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c).	
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Figure 35: Agap2 differential exons usage 
a. In the top graph Agap2 exon usage in Mll2-/- and Mll1+/+Mll2+/+ iNs. In the middle graph 
normalized read counts. In the bottom graph schematic of the differentially used exons. The 
statistically significant ones are in purple. Mll2-/- is in blue and Mll1+/+Mll2+/+ in red. b. FPKM of 
Agap2 in our RNA-seq. Means and SD are reported. *t test with a FDR <0.01. c. Ensembl 
schematic of the correspondence between exons and protein domains. d. Agap2 Refseq genes from 
UCSC Genome browser. Assembly Mouse December 2011 GRCm38/mm10. In the purple 
rectangle the alternative spliced exon between the two isoforms. 
 
Also Grin2b and Pdcd5, 2 of the top 30 differentially expressed genes (Figure 30), were 
subjected to alternative exon usage in the knock-out with respect to the control (i.e., 
respectively exons 2, 3 and 4 and exons 3, 4 and 6) (Figures 36a and 36b respectively). 
Both genes have only one isoform annotated (respectively NM_008171 and NM_019746) 
(Figures 36c and 36d). In the case of Grin2b the exon 4 belongs to a known domain, the 
extracellular binding one (Figure 36e), while we were not able to determine the 
correspondence of the other exons with specific domains. 
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Figure 36: Grin2b and Pdcd5 differential exons usage 
a. and b. In the top graph Grin2b (a.) and Pdcd5 (b.) exon usage in Mll2-/- and Mll1+/+Mll2+/+ iNs. 
In the middle graph normalized read counts. In the bottom graph schematic of the differentially 
used exons. The statistically significant ones are in purple. Mll2-/- is in blue and Mll1+/+Mll2+/+ in 
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red. c. and d. Grin2b and Pdcd5, respectively, Refseq genes from UCSC Genome browser. 
Assembly Mouse December 2011 GRCm38/mm10. e. Ensembl schematic of the correspondence 
between exons and protein domains of Grin2b gene.  
 
Myosin 10 (Myo10) has only one validated isoform (NM_019472) (Figure 37c) and it has 
been recently associated with neuronal migration during development thanks to the 
interaction of its FERM domain with N-cadherin172. This domain remained unaffected, 
since the differential used exons were the 1, 2, 3, 4, 11, 12, 18, 19, all belonging to the 
myosin head motor domain (Figure 37a and 37b). 
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Figure 37: Myo10 differential exons usage 
a. In the top graph Myo10 exon usage in Mll2-/- and Mll1+/+Mll2+/+ iNs. In the middle graph 
normalized read counts. In the bottom graph schematic of the differentially used exons. The 
statistically significant ones are in purple. Mll2-/- is in blue and Mll1+/+Mll2+/+ in red. b. Ensembl 
schematic of the correspondence between exons and protein domains of Myo10 gene. c. Myo10 
Refseq gene from UCSC Genome browser. Assembly Mouse December 2011 GRCm38/mm10.  
 
The SH3 and PX domain-containing protein 2A (sh3pxd2a) gene encodes for a protein 
necessary for matrix digestion and therefore, for axon extension173. The differential used 
exons were 2, 3, 5, encoding for the phox homologous domain, which confers affinity to 
PI-3,4-bisphosphate, and exons 6 and 7, encoding for part of the SH3 domain (Figures 38a 
and 38b). In particular exon 6 is the spliced exon between the two validated isoforms (i.e., 
NM_008018.4 long isoform 1; NM_001164717 short isoform 2) (Figure 38c). The isoform 
1, which has been associated with a higher invasion rate of metastatic cells174, was more 
expressed than the isoform 2 in our datasets, with no differences between the knock-out 
and the control (Figure 38d). Recently a new isoform was described, which loses the first 5 
exons and has an alternative start codon upstream of exon 6, which is quite similar to the 
Mll2-/- sh3pxd2a175, but with exon 6 and 7. 
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Figure 38: Sh3pdx2a differential exons usage 
a. In the top graph Sh3pdx2a exon usage in Mll2-/- and Mll1+/+Mll2+/+ iNs. In the middle graph 
normalized read counts. In the bottom graph schematic of the differentially used exons. The 
statistically significant ones are in purple. Mll2-/- is in blue and Mll1+/+Mll2+/+ in red. b. Ensembl 
schematic of the correspondence between exons and protein domains of Sh3pdx2a gene. c. 
Sh3pdx2a Refseq genes from UCSC Genome browser. Assembly Mouse December 2011 
GRCm38/mm10. In the purple rectangle the alternative spliced exon between the two isoforms. d. 
FPKM of the two Sh3pdx2a isoforms in our RNA-seq. Means and SD are reported. 
 
The SH3/ankyrin domain gene 3	(Shank3) is a gene involved in post-synaptic organization 
and dendritic spine maturation. Its microdeletion and point mutation have been associated 
with autism. Shank3 has a finely tuned post-transcriptional regulation and its alternative 
splicing, modulating the protein domains composition, could regulate its function and 
localization176. Despite this, only one isoform has been validated (i.e., NM_021423) 
(Figure 39e). In our RNA-seq Shank3 was down-regulated in Mll2-/- iNs (Figure 39b) that 
showed also a lower usage of exons 4-10 (ankyrin repeat-containing domain), 13-16 (PSD-
95/Discs large/ZO-1	PDZ domain), 19, 21 and 22 (Pro and Sterile Alpha Motif (SAM) 
domains) (Figures 39a, 39c and 39d). The truncated form of Shank3 (i.e., without SAM 
and Pro domains) has been shown to preferentially localize in the nucleus and on the basis 
of domains composition, when overexpressed, it either increases or decreases the spine 
density and length176. Our isoform has not been described in literature, but we can 
hypothesize that, since shank3 was both down-regulated and with only the SH3 domain, 
the post-synaptic compartment in Mll2-/- iNs could also be altered.		
d	
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Figure 39: Shank3 differential exons usage 
a. In the top graph Shank3 exon usage in Mll2-/- and Mll1+/+Mll2+/+ iNs. In the middle graph 
normalized read counts. In the bottom graph schematic of the differentially used exons. The 
statistically significant ones are in purple. Mll2-/- is in blue and Mll1+/+Mll2+/+ in red. b. FPKM of 
Shank3 in our RNA-seq. Means and SD are reported. * FDR<0.01 c. Ensembl schematic of the 
correspondence between exons and protein domains of Shank3 gene. d. Schematic of SHANK3 
protein domains and promoters modified from Wang et al., Molecular Autism 2014176. In red the 
alternative spliced exons. e. Shank3 Refseq gene from UCSC Genome browser. Assembly Mouse 
December 2011 GRCm38/mm10. In the purple rectangle the alternative spliced exon between the 
two isoforms.  
 
The X-linked inhibitor of apoptosis proteins (XIAP) anti-apoptotic function is counteracted 
by the X-linked IAP-associated factor-1 (XAF1), which shows a fine-tuned regulation, for 
example, during motoneurons apoptosis along development177. Two isoforms of Xaf1 have 
been validated: a full length isoform (i.e., isoform 1 NM_001037713) and a shorter one, 
without the exons 3 and 4 (i.e., isoform 2 NM_001291153) (Figure 40b). Only the isoform 
1 was detected in our datasets. However Mll2-/- Xaf1 transcripts presented a lower usage of 
exon 4 and 5, preserving the exon 6, which was instead lost in Mll2+/+ Xaf1 transcripts 
(Figure 40a). The protein N-terminus part, which contains a zinc finger domain 
fundamental for the interaction with XIAP, was therefore maintained in both variants. It 
has been shown that a truncated form of Xaf1 functions as dominant negative178, however 
in our case, the exon 6 was preserved. Hence further investigations should be needed. 
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Figure 40: Xaf1 differential exons usage 
a. In the top graph Xaf1 exon usage in Mll2-/- and Mll1+/+Mll2+/+ iNs. In the middle graph 
normalized read counts. In the bottom graph schematic of the differentially used exons. The 
statistically significant ones are in purple. Mll2-/- is in blue and Mll1+/+Mll2+/+ in red. b. Xaf1 Refseq 
genes from UCSC Genome browser. Assembly Mouse December 2011 GRCm38/mm10. In the 
purple rectangle the alternative spliced exons between the two isoforms. In red the alternative 
spliced exons. 		
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7.9 Identification of MLL2 direct targets 
7.9.1 ESCs with EGFP-tagged MLL2  	
Since the antibody for MLL2 is not exploitable for ChIP, our first strategy was to import 
ESCs, through a collaboration with Francis Stewart’s laboratory, with both copies of the 
endogenous Mll2 exons 2 flanked by loxP sites and harbouring a BAC (that recapitulates 
the endogenous regulation of Mll2) carrying an EGFP tagged version of MLL276. In 
particular EGFP has been inserted at the N-terminus of the taspase cleavage site (Figure 
41a). This does not affect MLL2 activity and upon exon 2 deletion the MLL2 encoded by 
the BAC can rescue the defects due to the absence of the endogenous Mll276.  
Therefore we needed a protocol to differentiate ESCs into either generic fibroblasts or, 
even better, into MEFs, the starting population of all our transdifferentiation experiments 
(Figure 41b).  
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Figure 41: Identification of the MLL2 direct targets 
a. Schematic of the imported EGFP-MLL2 ESCs. b. Approaches for the ESCs differentiation into 
fibroblasts. c. Once fibroblasts will be obtained they will be treated with 4-OHT and ChIP-seq will 
be performed at day 5 of transdifferentiation. 
  
We could not find in literature mESCs in vitro differentiation protocols, most likely 
because mouse fibroblasts represent a highly accessible cell-type. Hence, we adapted a 
protocol used for human ESCs differentiation that entails the formation of embryoid bodies 
and several passaging steps of cells in trypsin139. Unfortunately, at the end of the protocol 
we were not able to obtain fibroblasts like-cells. Indeed both among control and tagged 
differentiated ESCs, there were cells positive for pluripotency markers and other 
uncharacterized cells (Figures 42a and 42b). 
 
Figure 42: Mixed population by in vitro ESCs differentiation 
Representative images of differentiated control ESCs (E14TG2alpha) (a.) and ESCs MLL2-EGFP 
tagged (b.) tested for the presence of stem cells (left panels, DAPI is in blue and Oct4 in red), of 
neurons and fibroblasts (middle panels, DAPI is in blue, Vimentin in red and Tuj1 in green) and of 
oligodendrocytes (right panels, DAPI is in blue and Olig2 in red).  
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Subsequently we tried two alternative approaches: i) we injected the tagged ESCs into 
blastocysts, with the purpose of deriving MEFs from chimeric embryos; and ii) we 
cultured ESC-derived teratoma cells to allow the ESCs first to differentiate in vivo into the 
three different germ layers and only later, when explanted, to be positively selected for 
fibroblasts. 
We performed four rounds of blastocyst injections, then implanted in 8 pseudo-pregnant 
females, observing a very high rate of abortion (we recovered only 1 or 2 embryos per 
female with respect to the 4-5 commonly retrieved) (Figure 43a). This should not be 
attributed to the overexpression of Mll2 because ESCs carry only 1 additional copy of the 
gene (Figure 43c). We assayed the rate of chimerism through the TaqMan assay for the 
Mll2 exon 2, because the BAC encoded-EGFP is not visible at the microscope. When we 
analysed the recovered embryos they did not show more than 2 copies of Mll2 (Figure 
43d). Also after culturing the EGFP+ MEFs (Figure 43b) with G418, exploiting the 
selection cassette present in the BAC, we could not detect any increase in the exon 2 copy 
number (Figure 43e). Therefore, the concentration of G418 we used was probably too low 
to select only the BAC-engineered MEFs. When I increased the level of G418 in the 
medium, most of the cells died, confirming the low level of chimerism. The few MEFs still 
alive, instead, senesced becoming unusable for high-throughput studies, which envisage 
high numbers of cells. Moreover, since senescence per se could affect transdifferentiation, 
these MEFs were useless. 
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Figure 43: Chimeras formation 
a. Representative picture of one retrieved embryo (left panel) b. Genotyping of EGFP of chimeric 
MEFs. c. Exon 2 Mll2 copy number of ESCs MLL2-EGFP tagged assayed by TaqMan. d. Exon 2 
Mll2 copy number of chimeric MEFs at passage 0 assayed by TaqMan. e. Exon 2 Mll2 copy 
number of chimeric MEFs number 4 and 5 after 2 weeks of G418 selection, assayed by TaqMan. 
Wt: wild type. 
 
In the case of teratoma formation, we injected bilaterally and subcutaneously in 2 females 
NOD/SCID IL2Rγ-/- 106 ESCs previously maintained in culture with G418. After less than 
one month we collected 2 teratoma masses (Figure 44a). Part of them was sectioned and 
stained with haematoxylin/eosin to assess the trilineages specification that was indeed 
confirmed (Figures 44c and 44e), but some transformed areas were identified (Figure 44e). 
We also performed an immunohistochemistry staining for EGFP (Figure 44d). 
Interestingly we observed a widespread localization of EGFP (and therefore, indirectly, of 
MLL2) that was both nuclear and cytoplasmic (Figure 44f). We then cultured the teratoma-
derived-cells in the MEFs medium, containing serum, to positively select only fibroblasts. 
Teratoma cells presented the same Mll2 exon 2 copy number as the ESCs from which they 
derived (Figure 44b), but after 11 passages with trypsin we detected the appearance of 
water	1	 2	 3	 4	 5	1	Kb	
a	 b	
c	 d	 e	
		 126	
colonies (Figure 44g) that expressed pluripotency markers (Figure 44h), pointing to a 
probable transformation of the cells. Indeed cells appeared to have lost the contact 
inhibition and were growing faster with respect to the first passages.   
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Figure 44: Teratoma formation 
a. Teratoma masses explanted. b. Exon 2 Mll2 copy number of teratoma cells and wild type 
fibroblasts assayed by TaqMan. c. and e. Haematoxylin/eosin staining of teratoma respectively in a 
low and a high magnification. d. and f Immunohistochemistry staining for EGFP of teratoma 
respectively in a low and a high magnification. g. Representative images of teratoma cell culture at 
passage 11 in a low (on the left) and a high (on the right) magnification. h. Representative image of 
teratoma cell culture stained for Oct4 (DAPI is in blue and Oct4 in red). 
 
7.9.2 Identification of the MLL2 direct targets through MENIN  	
Since MLL2-EGFP tagged ESCs were not exploitable to assess MLL2 targets during 
transdifferentiation, we undertook a different strategy.  
MENIN is the common subunit of only MLL1 and MLL2 TrxG proteins and it is 
fundamental for the positioning at their specific targets43,55-57. Moreover there are ChIP-
grade commercially available anti-MENIN antibodies. Therefore we envisaged MENIN 
ChIP-seq, 5 days after cells were plated for transdifferentiation, in Mll1+/+Mll2+/+ and Mll2-
/- transdifferentiating MEFs as alternative approach. 
Through the immunoprecipitation of MENIN in Mll1+/+Mll2+/+ samples we could 
theoretically obtained an overview of the targets of both methylases at the peak of cell 
conversion. On the contrary, by performing MENIN ChIP-seq in Mll2-/- cells, we could 
identify the MLL2 specific targets, that are not compensated by MLL1 by comparing the 
ChIP peaks that are lost or reduced in the knock-out with respect to the control. 
Since MENIN ChIP-seq was not very sensitive at the level of peak-calling, with a large 
variability in terms of number of peaks per sample, we decided to proceed with a 
quantitative, peak-call-agnostic method for the identification of differentially-enriched 
regions. This analysis identified a very large number of sites with reduced enrichment in 
the knock-out, along with a small number of up-regulated sites, most likely representing 
compensation by Mll1 (Figure 45a). These sites overlapped with the promoters of, 
respectively, 839 and 213 genes. When we performed the GO analysis for the top most 
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specific biological processes, we observed that the genes with a reduction in MENIN 
binding in Mll2-/- iNs were related to the basic metabolism and function of the cell (Figure 
45d). On the contrary the genes that acquired MENIN binding in Mll2-/- iNs, were mostly 
connected to the acquisition of a different cell fate (Figure 45e). The subset of those genes 
that was differentially-expressed at day 13 is shown in Figure 45b. 	
In particular, Magohb, the best characterized direct MLL2 target so far64 was both 
differentially MENIN-bound and lower expressed in the knock-out. In addition, relying on 
interactions observed in Hi-C data from mouse neural progenitors, we identified 98 
additional target genes likely to be in contact with a region with reduced MENIN binding 
in the knock-out, including however only 3 genes that were differentially-expressed 
(shown in Figure 45c).	
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Figure 45: MENIN ChIP-seq 
a. Volcano plot of the differentially bound MENIN regions, in Mll2-/- with respect to control. b. 
Heatmap of the differentially bound MENIN genes (proximal) that were also differentially 
expressed (FDR <0.01 and a FC > 0.5). The colour scale (-2 blue to +2 yellow) represents Z-Score. 
c. Heatmap of the differentially bound MENIN genes (distal) that were also differentially 
expressed (FDR <0.01 and a FC > 0.5). d. and e. Quilts of the top most enriched Biological 
Process, respectively for the genes with a lower and a higher MENIN binding in Mll2-/- 
transdifferentiating MEFs. 	
7.9.3 H3K4 MLL2-deposited methylation during transdifferentiation 	
To identify the fundamental targets that need to be methylated to drive transdifferentiation, 
we performed H3K4me3 ChIP-seq 5 and 13 days after Mll1+/+Mll2+/+ and Mll2-/- MEFs 
were plated for transdifferentiation. In particular, in the 5 days H3K4me3 ChIP-seq, we 
included also one Mll1-/- transdifferentiating MEFs sample. 
The list of samples analysed is reported in Table 7. 
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Table 7: List of samples analysed by H3K4me3 ChIP-seq  
L6 and L7 transdifferentiating MEFs derived from different embryos, such as M6 and M7.  
 
First we performed a Principal Component Analysis (PCA) on the logarithmic normalized 
read counts across the union of H3K4me3 sites (Figure 46a). Interestingly, and as expected 
by the previously demonstrated lack of impact of the absence of MLL1 on 
transdifferentiation, Mll1-/- transdifferentiating MEFs clustered together with the controls 
(i.e., L6 and L7). Hence, either MLL1 is dispensable during MEF-to-iNs cell conversion or 
MLL2 can compensate for its absence, trimethylating MLL1-targets. This was in line with 
the published role of MLL1 and MLL2 during retinoic acid-driven ESCs differentiation 
into neurons76. Indeed it was demonstrated that it is MLL2 the main H3K4 trimethylase at 
bivalent promoters and that in Mll1-/- ESCs, MLL2 can compensate, trimethylating MLL1 
targets. On the other side, contrarily from what has been shown for SVZ NSC 
differentiation123, MLL1 during transdifferentiation is dispensable for the neuronal 
specification. Noteworthy a reduction in H3K4me3 at specific targets was not observed in 
Mll1-/- SVZ NSC pointing, also in this case, to a possible compensation by MLL2. 
Afterwards, if two lines were drawn between the Mll2-/- and the controls and between the 
day 5 and the day 13, they would be almost orthogonal. Moreover the displacement 
between controls and knock-out was parallel between day 5 and day 13 (Figure 46a, green 
arrows), as the displacement from day 5 to day 13 between controls and knock-out (Figure 
46a, light blue arrows). This suggested that the global mis-deposition of H3K4me3 in Mll2-
/- transdifferentiating MEFs was maintained, and mostly unchanged in Mll2-/- iNs. 
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For this reason, first we executed an analysis considering all samples together and 
adjusting for the differences linked to time points. Among 15405 sites marked by 
H3K4me3 in at least one sample, 1089 were statistically differentially marked in Mll2-/- 
and controls (FDR<0.01) (Figure 46b). In particular 994 sites, mapping at TSS of 545 
genes, showed a decreased H3K4 trimethylation, while 95 sites, mapping at the TSS of 82 
genes, showed an increase in H3K4 trimethylation. Among the 82 genes only Runt-related 
transcription factor 1 translocated to 1 (Runx1t1) was differentially expressed and, 
accordingly to its increased H3K4 trimethylation, was up-regulated in Mll2-/- with respect 
to controls (Figure 46e). Runx1t1 is a transcriptional co-repressor that recently has been 
implicated in RGs differentiation. However, if overexpressed it favours neuronal 
differentiation179. 
Of the 545 genes that showed a decrease in H3K4 trimethylation, 184 were differentially 
expressed at FDR<0.05 and 143 at FDR<0.01. In particular if we performed GO 
enrichments analysis on them, we observed, among the biological process, synaptic 
transmission and membrane transport (Figure 46c). Among the cellular components we 
could find especially membranes, synapses and dendrite, axon and neuron projections 
(Figure 46d). 
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Figure 46: H3K4me3 ChIP-seq 
a. PCA on the logarithmic normalized read counts across the union of H3K4me3 sites. Dashed 
green arrows represent the displacement between controls and knock-out at day 5 and day 13. 
Dashed light blue arrows represent the displacement between day 5 and day 13 in knock-out and 
controls. b. Volcano plot of the differentially H3K4 trimethylated regions. c. Quilt of the gene 
ontology enrichment analysis, regarding the biological processes, of the genes both differentially 
H3K4 trimethylated and expressed (FDR<0.01 and a FC > 0.5). d. Quilt of the gene ontology 
enrichment analysis, regarding the cellular components, of the genes both differentially H3K4 
trimethylated and expressed (FDR<0.01 and a FC > 0.5). e. f. and g. FPKM, in our RNA-seq, 
respectively of Runx1t1, of the genes that showed a decrease in H3K4me3 and were differentially 
expressed and of Tuba4a. Means and SD are reported * FDR<0.01 
 
Of the 143 genes, 13, according to MENIN ChIP-seq, can be considered direct targets of 
MLL2: Slc2a3, Arnt2, Chst10, Creld1, Gnao1, Phactr2, Rtn1, Sntb1, St6galnac3, Tifa, 
Tmem45a, Zfp239 and Zfp27. Moreover, in line to their reduced H3K4 trimethylation, they 
were down-regulated in Mll2-/- with respect to controls (Figure 46f). 
The solute carrier family 2 member 3 (Slc2a3) or Glut-3 is a brain specific glucose 
transporter, while the guanine nucleotide binding protein, alpha O (Gnao1) is a brain-
specific G protein coupled receptor associated to epilepsy180.  
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The Aryl hydrocarbon receptor nuclear translocator 2 (Arnt2) has been implicated in 
zebrafish and mouse brain development. In particular it has been shown to be bivalently 
marked in ESCs and to be induced, upon demethylation of H3K27, during retinoic acid 
induced-ESC differentiation181. 
The carbohydrate sulfotransferase 10 (Chst10) is an enzyme, which synthesised the 
neuronal specific sulfoglucuronyl carbohydrate, involved, among the others, also in neurite 
outgrowth182. 
The phosphatase and actin regulator 2 (Phactr2) is a brain specific protein induced upon 
injury, during neurogenesis183. 
The reticulon 1 (Rtn1) has three isoforms: Rtn1-a, Rtn1-c and Rtn1-c1. In our datasets only 
Rtn1-a and Rtn1-c were expressed and Rtn1-a more than Rtn1-c. Isoform a has been 
associated with neuronal excitation: it encodes for an endoplasmic reticulum membrane 
protein coupled with the ryanodine receptor 2, which modulates calcium oscillation184. 
Isoform c, instead, modulates histone deacetylases activity185. 
Zfp239 and Zfp27 are poorly characterized, but because of their ability to bind DNA, and 
RNA in case of Zfp239186, they are two interesting candidates as MLL2 mediators. 
All the other genes are poorly described in literature or without a clear connection with 
neuronal differentiation. 
Finally, we looked also at the differentially expressed genes that were bound by MENIN in 
the control and without any peak in the knock-out and differentially H3K4me3. The only 
gene which came out from this analysis was the tubulin alpha 4 a (tuba4a) (Figure 46g), a 
specific tubulin with its highest expression in brain and whose mutation is associated to 
familial amyotrophic lateral sclerosis187. 
Therefore MLL2 emerges from these data as having a key role for the modulation of genes 
implied in the acquisition of neuronal functions and metabolism. However few genes came 
out from the integrative analysis of the H3K4me3 ChIP-seq, the MENIN ChIP-seq and the 
RNA-seq, probably because the RNA-seq and MENIN ChIP-seq were performed on 
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different time points. Therefore through the RNA-seq at 13 days we could observe only the 
downstream effectors of MLL2 and not its direct targets. 
Next, we thus looked at the genes differentially bound by MENIN and differentially H3K4 
trimethylated, without considering their expression level (Figure 47a). Indeed, although 
changes in MENIN and H3K4me3 enrichments did not always lead to the corresponding 
change in gene expression, the majority of the genes showed reduced MENIN binding and 
had a lower level of H3K4me3 in Mll2-/- cells. These genes could be considered as the 
direct targets of MLL2, not compensated by MLL1.  
Among the most interesting ones there was Zfp277, a transcriptional repressor that through 
the interaction with the PRC1 complex component BMI1 (up-regulated in Mll2-/- iNs), is 
involved in the Ink4a/Arf locus silencing188. Of note, Bmi1 itself and Chromobox 7 (Cbx7) 
were also differentially-expressed in Mll2-/- iNs (Figure 47b), and the differentially-
expressed genes were enriched for targets of PRC2 (~2-fold enrichment, FDR ~4e-75) in 
mESCs, suggesting that the Polycomb axis of regulation might be responsible for part of 
the dysregulation caused by Mll2 depletion during transdifferentiation. In addition, the 
patched homolog 1 (Ptch1), the receptor of the sonic hedgehog (sh) ligand, is involved in 
the Sonic Hedgehog pathway that is fundamental, in vivo, for axon guidance189. Moreover 
the dedicator of cytokinesis 4 (Dock4), a guanine nucleotide exchange factor for Rac1, has 
been shown to regulate axon-dendrite polarity and dendrites arborisation190,191. A truncated 
mutation of Dock4 affects neurite elongation192. Interestingly, also Mll1-/- 
transdifferentiating MEFs showed a reduced H3K4 trimethylation at day 5, pointing to the 
necessity of the presence of both methylases for its trimethylation. The neuralized homolog 
1 a (Neurl1a) is an E3 ubiquitin ligases that in hippocampal neurons activates CPEB3, 
whose in turn induces glutamate A1 (GluA1) and GluA2 (GluA2 was down-regulated in our 
dataset Figure 47c), important for synapse plasticity193. The Drosophila homolog is 
fundamental for neurogenesis. Indeed, in the fly Notch signal receiving cells, during lateral 
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inhibition process, neuralized ubiquitinates the Delta ligand causing its internalization and 
consequently its degradation194,195. 
A second category of genes was not bound by MENIN, but H3K4 trimethylated in Mll2+/+ 
cells and bound by MENIN, but not H3K4 trimethylated in Mll2-/- cells. We subdivided 
these genes among i) the ones that are stably expressed throughout transdifferentiation 
(Nipal1 and Lhx6), that therefore are already trimethylated at the time point analysed, ii) 
the ones that are activated earlier (2 days after BAM transduction (Syt1) in which, most 
likely the trimethylation, and therefore the MLL2 binding, occurred earlier than the 5 days-
time point analysed and iii) the one whose expression is independent from H3K4me3 
(Csrp2) (Figure 47d). The hypothesis for this category of genes is that either the H3K4me3 
was deposited by MENIN-containing complexes earlier with respect to the time point 
analysed, and therefore MENIN is no more detectable through ChIP, or that the H3K4me3 
deposition at these genes was performed by another TrxG member. In Mll2-/- cells a 
mechanism of compensation probably led to MENIN mis-binding, which however failed in 
H3K4 trimethylation, not present even at 13 days. Alternatively MENIN in the knock-out 
could function as a repressor, interacting, for example, with the Suppressor of variegation 
3-9 homolog 1 (Suv39h1) for the deposition of H3K9 methylation196. However, among 
them, only Syt1 was down-regulated in our dataset, a gene fundamental during 
transdifferentiation, further suggesting a more probable mislocalization of MENIN (Figure 
28).  
A third category was constituted by the genes bound by MENIN, but not H3K4 
trimethylated in Mll2+/+ cells and not bound by MENIN, but H3K4 trimethylated in Mll2-/- 
cells (Nol10, Imp4, Ccdc115, Wdr5 and Leng8). Surprisingly, for this class of genes the 
MLL2-MENIN binding seemed to prevent the H3K4me3 deposition, that was instead 
acquired in Mll2-/- iNs, where the MENIN binding was absent. Interestingly one of them 
was the common component of COMPASS complexes50,51Wdr5 that, besides having a 
stable expression along transdifferentiation (Figure 47e), in Mll2-/- cells acquired H3K4 
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trimethylation, probably also for a compensatory mechanism, but failed to be more 
expressed in the knock-out with respect to the control iNs (Figure 47g). 
The taurine upregulated 1 (Tug1) and the MORC family CW-type finger protein 2A 
(Morc2a), instead, were bound by MENIN and H3K4 trimethylated in Mll2-/- cells. This 
was probably the result of the mislocalization of the trithorax COMPASS-like complexes 
in absence of MLL2. The two genes are stable during transdifferentiation (Figure 47f). In 
particular, Tug1 is a long noncoding RNA induced by p53 that associates with PRC2 and 
regulates many cell cycle genes197. 
Finally the H3K4me3 mark was erased from Ephrinb2 (Efnb2) (important for neuronal 
migration during development198) at 13 days independently from both the genotype and the 
MENIN binding, indicating that the H3K4me3 deposition and erasure on this gene was not 
associated to MLL2. Efnb2 is up-regulated 2 days after BAM transfection and down-
regulated at 13 days (Figure 47h). In Mll2-/- iNs it failed to be down-regulated as in Mll2+/+ 
iNs, despite the erasure of H3K4me3 mark (Figure 47i). 
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Figure 47: Analysis of the genes differentially H3K4me3 and MENIN bound 
a. Heat map of the genes differentially H3K4 trimethylated and MENIN bound in Mll2-/- and 
controls. The colour scale (-2 blue to +2 yellow) represents Z-Score. b. c. g. and i. FPKM in our 
RNA-seq at 13 days of respectively  Polycomb components, GluA2, Wdr5 and Efnb2. Means and 
SD are reported. d. e. f. and h. RPKM, during transdifferentiation, of the genes differentially H3K4 
trimethylated and MENIN bound. Means and SD are reported. Source data: Wapinski et al., Cell 
2013106. * FDR<0.01 
 
Moreover the majority of the genes belonging to the first category had a further decrease in 
H3K4 trimethylation at 13 days. Therefore we performed another analysis focused only on 
this time point.  
112 genes showed a lower H3K4me3 enrichment in Mll2-/- iNs with respect to Mll2+/+ on 
the same day. Among them, 40 were differentially expressed (Figure 48). As expected, all 
the genes that showed a further H3K4 demethylation at 13 days, in Mll2-/- 
transdifferentiating MEFs, were down-regulated in Mll2-/- iNs. 
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Figure 48: Analysis of the genes with reduced H3K4me3 at 13 days 
Heat map of the genes that further lost H3K4 trimethylation at 13 days and their expression in 
RNA-seq at 13 days. The colour scale (-2 blue to +2 yellow) represents Z-Score. 											
 
Row	Z-Score	
		 143	
8. DISCUSSION 
 
In this thesis I defined the role of MLL1 and MLL2 during MEFs-to-iNs BAM-driven 
transdifferentiation. MLL1 and MLL2 are two H3K4 trimethylases, historically discovered 
for their function in maintaining the expression of Hox genes51,55,77, important during both 
development and differentiation. Furthermore both enzymes were shown to exert 
fundamental roles during neuronal differentiation. Indeed ectodermal in vitro 
differentiation of Mll2-/- ESCs is impaired84, while in Mll1-/- ESCs, MLL2 can compensate, 
trimethylating MLL1-targets genes76. The ablation of Mll2 in excitatory forebrain neurons 
leads to memory defects, but does not impinge brain morphology125. The neuronal 
differentiation of Mll1-/- SVZ NCS is impaired and this is not due to a reduction in 
H3K4me3 mark deposition, but to the absence of the erasure of the H3K27me3 at 
important target genes123. On the contrary, the absence of MLL1 during Danio rerio 
development reduces neural progenitors proliferation, anticipating neuronal 
differentiation124.  
It is therefore conceivable that MLL1 and MLL2 are involved in the conspicuous 
epigenome resetting that allows the conversion between MEFs and iNs, two cell types so 
embryologically distant. Therefore I investigated how the absence of MLL1 and/or MLL2 
affects transdifferention. 
 I took advantage of mouse models conditional knock-out for Mll1128, Mll256 or their 
compound strain, in a tamoxifen inducible system. Interestingly, when I assessed the 
MLL2 level through western blot, despite the fact that in ESCs both the full length and the 
active taspase-cleaved MLL2 were present, in MEFs only the uncleaved protein was 
observed, which, as expected, disappeared upon 4-OHT treatment. This suggests that in 
MEFs, Mll2 is translated, but it is inactive. When I evaluated the level of Mll2 mRNA 5 
and 13 days (both through RT-qPCR and through RNA-seq) after cells were plated for 
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transdifferentiation, I did not observe a decrease in the level of Mll2 transcript due to 
nonsense-mediated decay, probably because MLL2 is maintained inactive in MEFs.  
 
First I showed that MLL1 is dispensable for the MEFs-to-iNs direct conversion. The 
efficiency of transdifferentiation of Mll1-/- cells was reduced at FACS, but this was 
paralleled by their higher cell death (Figure 49b). Moreover the percentage of PSA-
NCAM+ Mll1-/- cells was fully overlapping to the one of control, along the entire 
transdifferentiation process, suggesting that the proportion of dying cells was the same 
among PSA-NCAM+ and PSA-NCAM- cells. Hence the reduced transdifferentiation 
efficiency that we observed was the indirect consequence of the affected cell viability in 
cells deprived by MLL1 (Figure 49b). Indeed MLL1 was demonstrated to be associated to 
cell cycle regulator genes83, but although the straight knock-out embryos showed a 
widespread cell death at E.10.555, there are no any other evidences that directly connect 
MLL1 deletion to apoptosis. Recently it was demonstrated that endoplasmic reticulum 
stress-induced apoptosis is enhanced in Mll1-/- MEFs199, however cell death was not the 
consequence of MLL1 deletion. Because the proportion of dead cells was the same among 
iNs and untransdifferentiated cells, we could not state that it is the transdifferentiation 
process per se that causes cell death in an already compromised starting cell. Most likely 
MLL1 activates anti-apoptotic genes independently from the considered cell type and state.  
In ScanR experiments the efficiency of transdifferentiation of Mll1-/- cells varied 
depending on the cell mortality rate, but MEFs were plated for BAM factors transduction 
immediately after 4-OHT.  Despite the fact that there is no effective anti-MLL1 antibody 
(reactive with mouse), we can be quite confident about its degradation, also in this 
experimental setting. Indeed, it has been shown that MLL1 is degraded each late S and M 
phase78. MEFs cultured in low oxygen and at low passages have a doubling time of ~ 
24h200. Therefore only two additional days before plating the cells for transduction, should 
be enough to ensure MLL1 degradation and the alteration in the transdifferentiation rate of 
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Mll1-/- cells, in this experimental setting, should be attributed to their altered cycling in the 
absence of MLL1. Indeed, depending on the level of cell cycle affection, we observed a 
lower or higher transdifferentiation efficiency. Finally Mll1-/- neurons had the same 
morphology and matured as well as control iNs, further underling that MLL1 is 
dispensable during transdifferentiation.  
When we performed H3K4me3 ChIP-seq on 5 days transdifferentiating MEFs, Mll1-/- cells 
clustered with Mll1+/+Mll2+/+ cells. Therefore, even if only in one sample, the H3K4me3 
redistribution, necessary for transdifferentiation, was not affected in the absence of MLL1. 
This on one side could be reconciled by the lack of a role for MLL1 during neuronal direct 
cell conversion. On the other side MLL2 could compensate its absence, trimethylating 
MLL1 specific targets.  
Therefore, although the Mll1 ablation is detrimental for SVZ NSC neuronal 
differentiation123, transdifferentiation can proceed even if this methylase is deleted, 
accordingly to its role during zebrafish development, where the usage of a specific 
morpholino against Mll1 does not impede, but it prematurely induces neuronal 
differentiation124. This is not counterintuitive because it is not presume, that 
transdifferentiation would undertake the same epigenetic changes of “physiologic” 
differentiation and is even more evident since the starting cells have completely different 
epigenomes.  
The defective neuronal differentiation of Mll1-/- SVZ NSC was specifically due to the lack 
of the erasure of H3K27 trimethylation at critical target genes. To exclude this option and 
to analyse if also for what concerns this histone mark, Mll1-/- transdifferentiating MEFs 
cluster with control, I have already performed the H3K27me3 ChIP-seq on 5 days Mll1-/- 
transdifferentiating MEFs, which will be analysed in the next future.  
 
In the case of Mll2-/- MEFs, plated 2 days after 4-OHT treatment, I observed an initial 
deficit in neuronal transdifferentiation, overcome at 13 days (both in FACS and in ScanR 
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experiments). If, instead, MEFs were plated for transdifferentiation one week after 4-OHT 
treatment the defect overcoming no more occurred (Figure 49c).  
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Figure 49: Schematic model of transdifferentiation in the different knock-out 
Transdifferentiation efficiency and mortality rate assuming to start from the same number of 
MEFs, left in culture 7 days after 4-OHT, before plating them for BAM factors transduction. 1- 
BAM factors transduction; 2- epigenetic remodelling; 3- cell populations observed at 13 days. a. 
Transdifferentiation of Mll1+/+Mll2+/+ MEFs. b. Transdifferentiation of Mll1-/- MEFs. Mortality rate 
is high with respect to Mll1+/+Mll2+/+ transdifferentiating MEFs, but iNs are mature. c. 
Transdifferentiation of Mll2-/- MEFs. Mortality rate is comparable to the one of Mll1+/+Mll2+/+ 
transdifferentiating MEFs, but iNs are immature and the efficiency of cell conversion is lower. d. 
Transdifferentiation of Mll1-/-Mll2-/- MEFs. Mortality rate is comparable to the one of Mll1-/- 
transdifferentiating MEFs; very few iNs are generated and they remain immature. 
 
We can confidently exclude that the absence of MLL2 would make MEFs less prone to 
transdifferentiation. Ascl1 primarily binds to trivalent chromatin states composed by 
H3K4me1, H3K27Ac and H3K9me106. Cells with few trivalent chromatin loci convert into 
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iNs at low efficiency. It has been demonstrated that MLL3 and MLL4 monomethylate 
H3K4 at enhancer67,71 and that in active enhancer H3K4me1 is associated with H3K27ac28. 
It is therefore conceivable that MLL3 and MLL4 are also responsible of H3K4 
monomethylation at trivalent chromatin states. MLL2 instead is mostly a H3K4 
trimethylase, which excludes its possible involvement in structuring the trivalent chromatin 
state. Moreover MLL1, the homolog of MLL2, is responsible for the H3K4 trimethylation 
of only 5% of the MEF promoter genes commonly marked by H3K4me351. Because MLL1 
and MLL2 possess some specific, but also some shared targets and since SET1A and 
SET1B are the main responsible for the deposition of H3K4me3 mark46, we could expect 
that MLL2, on average, would quantitatively trimethylate the same proportion of targets of 
MLL1. Therefore the deletion of MLL2 should not lead to a massive reorganization of 
H3K4me3 and should not affect the specific “MEFs genes” that make this cell type prone 
to transdifferentiation. However to formally prove it an ad hoc ChIP-seq should be 
performed on control and knock-out MEFs. On the other side, in Mll1-/- MEFs, 3% of the 
genes presented also a reduced expression, concomitantly to the reduced H3K4me351. In 
particular, these genes were involved in cell signalling and transcriptional regulation and 
among them also specific Hox genes were dysregulated. A change in cell 
identity/morphology was not reported in this study. Hence, most likely, the down-
regulation of these genes does not perturb the MEF lineage specification per se. However, 
since MLL2 has both specific and shared with MLL1 Hox targets, the alteration of Hox 
gene expression could affects the de novo acquisition of neuronal identity of Mll2-/- MEFs. 
However, in our analysis, Hox genes did not result dysregulated, excluding their possible 
involvement in the defective transdifferentiation observed in the absence of Mll2. 
Contrary to what has been demonstrated in different cellular types and contexts, such as in 
ESCs84, Mll2-/- MEFs showed the same cell death rate of control cells during 
transdifferentiation. Specifically, in Mll2-/- ESCs, the higher cell mortality was attributed to 
the down-regulation of Bcl-2, that was indeed lower expressed also in Mll2-/- iNs with 
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respect to control. However Pdcd5, which encodes for a protein released during apoptosis 
and that favours programmed cell death165,166, was down-regulated in Mll2-/- iNs and came 
out as one of the most differentially expressed genes. Moreover Bax, up-regulated in Mll2-
/- oocytes74, and Bad had similar levels of expression between knock-out and control iNs. It 
has been recently shown that when Bcl2 is co-transduced with Ascl1 during astrocytes-
neurons transdifferentiation, it favours the process of cell conversion in an apoptosis 
unrelated manner201. Therefore we could envisage that the lower expression of Bcl2 would 
further emphasize the reduced transdifferentiation efficiency of Mll2-/- MEFs, more than 
increasing its mortality rate. 
When I immediately plated Mll2-/- MEFs after 4-OHT treatment I did not observe any 
defect in transdifferentiation efficiency at 13 days both in FACS and ScanR experiments. 
This has two possible explanations. First, 5 days in 4-OHT plus 2 days in normal medium 
could be not sufficient for the degradation of MLL2 translated prior to the induction of Cre 
recombinase activity. In ESCs two days of 4-OHT treatment are enough to see the 
disappearance of the MLL2 protein. However in ESCs this methylase could have a 
different turnover rate since, as shown in our western blot, MLL2 seems active in ESCs 
and inactive in MEFs. To check this hypothesis a western blot for MLL2 in MEFs 2 days 
after the end of 4-OHT treatment has to be performed. However, at FACS, we anyway 
observed an initial defect in transdifferentiation in Mll2-/- cells. In a preliminary 
experiment, where I transdifferentiated Mll2-/- and Mll2+/+ MEFs, left in culture after 4-
OHT only 2 days, I observed that, after doxycycline administration, knock-out MEFs still 
proliferate. As I shown in the rest of the thesis, this was not the case for any of the MEFs 
plated one week after 4-OHT treatment, independently from their genotype, as previously 
published91. Despite the fact that a more comprehensive study of the Mll2-devoid MEFs 
cell cycle, before and along transdifferentiation, is needed, the proliferative advantage of 
Mll2-/- MEFs could explain the higher number of Mll2-/- iNs generated with respect to the 
number of plated cells. Proliferation is not required for neuronal transdifferentiation107, but 
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it would lead to start from a higher number of cells from which, consequently, more iNs 
would be obtained. Moreover, if the slower transdifferentiating MEFs, still PSA-NCAM-, 
at the beginning would continue to cycle, this would result in a lower percentage of PSA-
NCAM+ cells, that indeed we observed. Hence this model would better reconcile most of 
the observations done on cells immediately plated after 4-OHT. Despite the fact that 
MLL2, as MLL1, interacts with E2Fs proteins61, which in turn regulate cell cycle, in Mll2-/- 
ESCs there are no evidences that connect Mll2 deletion to an alteration either of the cell 
cycle or of the proliferation rate84. However this study was conducted in different cell type 
with respect to the one I used84, where the MLL2 function could be different. 
 
The role of MLL2 during transdifferentiation can thus be distinguished from the impact of 
its absence on cell cycle/cell mortality, plating MEFs one week after 4-OHT treatment. 
Therefore RNA-seq and ChIP-seq studies were performed only according to this 
experimental setting. What can be deduced from both the transdifferentiation kinetics and 
the transcriptomic/epigenomic studies is that the deletion of Mll2 impinges on 
transdifferentiation efficiency, but, more importantly, that Mll2-/- iNs fail to mature. This is 
partially in accordance with the results obtained with retinoic acid-mediated neuronal 
differentiation of ESCs, in which the deletion of Mll2 led to lower expression of 
“maturation genes” with respect to the controls, but mature neurons were anyway present 
in culture84. Moreover I showed that the absence of MLL2 severely affected neurite 
extension, independently from how many days after 4-OHT MEFs were plated, contrary to 
the conditional deletion of Mll2 in excitatory neurons in vivo, where a defect in 
neuronal/brain morphology was not observed125. 
Recently the network of genes involved in the MEF-to-iNs transdifferentiation has been 
described and further subdivided in three subnetworks: the MEF subnetwork, the initiation 
subnetwork and the maturation subnetwork, on the basis of the phase of the process that 
the specific group of genes regulates108. A conspicuous part of the maturation subnetwork 
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genes was indeed down-regulated in Mll2-/- iNs, such as also the genes previously shown 
by the same group to be up-regulated to allow transdifferentiation106. The only exception 
came from Zfp238, one of the main effector of Ascl1106. Zfp238, during the first 
transdifferentiation phases, was up-regulated also in Mll2-/- transdifferentiating MEFs, even 
if at a much lower extent, but it failed to be down-regulated at 13 days (assessed both 
through RT-qPCR and through RNA-seq). However it did not come out among the genes 
that lost the H3K4me3 at the end of the process. One possible hypothesis that will be tested 
in the next future through ChIP-seq, is that Zfp238 fails to be H3K27 trimethylated in the 
absence of MLL2. 
Among the differentially expressed genes, but also the differentially H3K4 trimethylated 
ones, a relevant fraction was connected to neurite elongation and synapse formation further 
corroborating the observed phenotype at the molecular level.  
 
When we analysed MENIN binding and the H3K4me3 mark distribution we observed that 
in Mll2-/- MEFs, 839 genes lost MENIN binding, pointing to the absence of a complete 
compensation of MLL1. The lack of a compensation by MLL1 is further suggested by the 
absence of an up-regulation of its mRNA in Mll2-/- iNs.  
On the other side 213 genes acquired de novo MENIN binding, suggesting either a 
mislocalization of the MLL1 and MLL2 COMPASS-like complex or a possible adaptive 
response of the cells to the absence of MLL2. From gene ontology analysis the genes, 
which lost MENIN binding, were related to basic cell functions and metabolism, while the 
genes that acquired MENIN binding were related to non neuronal cell identities, 
suggesting that the second hypothesis is the most plausible one.  
For what concerns the H3K4 trimethylation, 545 genes lost the mark, while 82 genes 
acquired it, further demonstrating that MLL2 targets specific loci during 
transdifferentiation, whose vulnerability to the loss of MLL2 is not compensated by 
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MLL1. Also in this case, the differentially expressed genes among them were related to 
neuronal maturation and synaptic transmission. 
Finally, among the differentially H3K4 trimethylated and MENIN bound genes, Zfp277 
was identified188. This zinc finger protein has been associated with BMI1, a component of 
PRC1 complex and, in our datasets, both Bmi1 and Cbx7 were differentially expressed 
between Mll2-/- and control iNs. Moreover the differentially expressed genes were enriched 
for PRC2 targets in mESCs. Therefore also the Polycomb axis could be the cause of the 
altered gene expression profile we observed in Mll2-/- iNs and, hence, of their maturation 
defects. Trithorax and Polycomb are two families of proteins with opposite and balanced 
functions. Indeed MLL2 prevents H3K27me3 deposition at specific targets63,64. Therefore 
it is plausible that, in the absence of MLL2 and without the compensation of MLL1, 
Polycomb would prevail, at least at some targets. 
I thus propose a model where the role of MLL2 during transdifferentiation is the H3K4 
trimethylation and induction of “neuronal maturation genes”. Hence, in its absence, 
transdifferentiation can start, even if less efficiently, but the generated iNs remain 
immature (Figure 50). In particular, to confirm this hypothesis, I will perform 
electrophysiological studies on Mll2-/- and control iNs.  
On the other side MLL1 cannot compensate for MLL2 absence, as it is the case, instead, 
during retinoic acid ESCs neuronal differentiation76. Hence, again, at least for what 
concerns MLL1-MLL2-H3K4me3 deposition, the differentiation following the 
Waddington descent and the crossing of the epigenetic hill are not comparable, probably 
both because the starting cells possess very different epigenomes and the two systems 
entail different “routes” to reach the neuronal identity. 
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Figure 50: Schematic model of transdifferentiation in the absence of MLL2 
Upon BAM factors transduction (1) MEFs start to transdifferentiate (2), probably through the 
recruitment of a still undefined epigenetic remodeller. However, the absence of MLL2, already 
affects the efficiency of this step. In iNs generated (3) MLL2 cannot trimethylates fundamental 
neuronal maturation genes (4). Therefore only iNs with short neurites are detected at 13 days (5).  
 
H3K4me3 has been linked to alternative splicing142-145, therefore we studied also if in 
absence of MLL2 this process is affected. Indeed we described few genes, but all subjected 
to a specific differential exon usage never described in literature. Moreover all genes were 
strictly linked to neuronal function and maturation. Strikingly the loss of both Mll1 and 
Mll2 severely affected iNs generation and morphology and led to an extremely high cell 
death (Figure 49d). In particular, despite the fact that the cell death rate was the same 
between Mll1-/- and Mll1-/- Mll2-/- transdifferentiating MEFs, the efficiency was lower in the 
double knock-out. This further demonstrates that it is indeed MLL2 the main Trithorax like 
COMPASS complex component responsible of H3K4me3 remodelling during 
transdifferentiation, while the absence of Mll1 only affects cell viability. 
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